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1. Introduction 
1.1 The control of food intake by the central nervous system 
Food intake is highly regulated. Despite the fact that composition and amount of food 
that we eat varies considerably from one meal and one day to the next, the cumulative 
energy intake is matched to energy expenditure with great precision when measured 
over a period that spans many meals (Schwartz et al. 2000). Disorders of food intake 
lead to obesity, a major risk factor for developing cardiac disease and type 2 diabetes 
mellitus (Broberger and Hokfelt 2001), or lead to anorexia in the course of chronic 
pathophysiological processes including cancer and infectious disease (Plata-Salaman 
2000). Both are associated with increased mortality. Recently, there has been a 
tremendous increase in our understanding of how the brain senses energy deficit and 
excess. The homeostatic regulatory systems are located mainly in the hypothalamus 
and brain stem (Berthoud 2004). Here, peptidergic neurons are found which serve as 
recipients of hormonal and nerval signals from the gastrointestinal tract, adipose tissue 
and other peripheral organs. These peptidergic cell populations project reciprocally to 
many other regions (Broberger and Hokfelt 2001). A multitude of neurotransmitters 
and peptidergic neuromodulators participate in these hypothalamic and brain stem 
"feeding pathways" and exert powerful effects on food intake. 
A milestone in the understanding of the neuropeptidergic regulation of body 
weight and food intake was the discovery of leptin, a hormone/cytokine produced by 
adipocytes that mediates satiety signals to the hypothalamus causing a reduction in 
food intake and loss of body weight (Zhang et al. 1994). Leptin circulates at levels 
proportional to body fat content and enters the CNS in proportion to its plasma levels 
(Schwartz et al. 1996). Administration of leptin directly into the brain reduces food 
intake (Campfield et al. 1995). Other hormones have opposite effects such as ghrelin, 
which is released from the stomach and sends orexigenic signals to the brain 
producing appetite and increased food intake (Inui 2001) resulting in weight gain 
(Tschop et al. 2000). The anorexigenic hormone amylin, which belongs to the 
calcitonin peptide family, is secreted from the endocrine pancreas and contributes to 
feeding-related changes of neuronal activity in the brain stem (Riediger et al. 2004). 
However, its precise role and sites of action in the brain stem and in the hypothalamus 
are less well studied. The current model of the hypothalamus and brain stem circuitry 
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involved in the action of peripheral signals on feeding-regulatory circuitry is 
illustrated in Fig. 1. 
PVN
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Fig. 1 A model of the action of peripheral signals on feeding-regulatory circuitry 
Peripheral signals related to long-term energy stores are produced by adipose tissue (leptin) and the 
pancreas (insulin). Leptin and insulin reduces food intake by acting on hypothalamic pathways, which 
originate in the arcuate nucleus (ARC) of the hypothalamus and project to the paraventricular nucleus 
(PVN) and the lateral hypothalamic area (LHA). Ghrelin is released mainly from the stomach to 
increase appetite and food intake by acting on hypothalamic neurons and the nucleus of the solitary 
tract (NTS) of the brain stem. The NTS of the brain stem plays an important role in mediating the 
anorectic effect of the pancreatic hormone amylin, which is co-secreted with insulin from the pancreas 
in response to food ingestion. The involvement of higher brain centers, especially hypothalamic 
structures, in the regulation of the anorectic effect of amylin remains to be investigated. A number of 
adipocyte-derived hormones adiponectin, resistin and visfatin are found to play an important role in the 
regulation of food intake and energy expenditure. Adiponectin increases insulin sensitivity. By contrast, 
resistin induces insulin resistance in obesity. Visfatin stimulates glucose uptake by adipocyte and 
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muscle cells and decreases blood glucose levels. (Modified after Schwartz et al. 2000 and Badman and 
Flier 2005). 
1.1.1 Feeding-related nuclei of the rodent hypothalamus 
The hypothalamus is the area of the diencephalon ventral to the hypothalamic sulcus. 
It is involved in a variety of functions including the control of anterior pituitary 
function through secretion of hypothalamic releasing factors (Murakami et al. 1991), 
control of brain stem and spinal cord autonomic centers related to cardiovascular 
(Michelini 2001), respiratory (Kc et al. 2002), and gastrointestinal functions (Grill and 
Kaplan 2001), control of body temperature (Boulant 2000), wakefulness and sleep 
(Hagan et al. 1999), and regulation of feeding behavior through hypothalamic satiety 
and feeding centers (Broberger and Hokfelt 2001). 
The mammalian hypothalamus consists of several nuclei involved in the 
regulation of food intake, including the arcuate nucleus (ARC), the paraventricular 
nucleus (PVN), the lateral hypothalamic area (LHA), the ventromedial nucleus 
(VMH), and the dorsomedial nucleus (DMH) (see Fig. 1) (Schwartz et al. 2000). The 
involvement of the hypothalamus in the regulation of feeding behavior was first 
shown in lesion studies (Hetherington and Ranson 1940) and in electrical stimulation 
experiments. These studies led to the development of the "Dual Center Model" for 
regulation of feeding, in which the medial part of the hypothalamus, in particular the 
VMH, was regarded as the "satiety centre", and the LHA as the "feeding centre". The 
"Dual Center Model" was based on the ability of electrical stimulation of the VMH to 
suppress food intake, and of bilateral VMH lesions to induce hyperphagia and obesity. 
Conversely, stimulation or lesioning of the LHA induced the opposite response. While 
these studies were strikingly precise in identifying the subregions of the hypothalamus 
in which circuits promote or suppress feeding, a major breakthrough in the 
understanding of the central regulation of feeding behavior was achieved with the 
identification of hypothalamic neuropeptides influencing feeding behavior such as 
neuropeptide Y (NPY; for review see Schwartz et al. 2000; Horvath and Diano 2004). 
The arcuate nucleus (ARC), located at the bottom of the hypothalamus 
surrounding the third ventricle, has been implicated in the control of feeding 
behaviour. Damage to this region in mice resulted in a phenotype of hyperphagia and 
obesity (Olney 1969). At least two distinct subnuclear regions can be distinguished in 
the ARC, a medial part consisting of neurons that co-express the orexigenic 
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neuropeptides NPY and agouti-gene-related protein (AgRP), and a lateral part 
consisting of neurons that co-express the anorexigenic neuropeptides pro-
opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript 
(CART). These two neuronal populations are called ‘first order neurons’ because they 
express the specific receptors for the peripheral adiposity factors such as leptin, which 
can modulate the activity of these neurons directly, due to the lack of the blood brain 
barrier (BBB) in the median eminence (ME), where the nerve terminals of arcuate 
neurons are in direct contact with the bloodstream (Hillebrand et al. 2002). Leptin 
regulates body weight via interaction with specific leptin receptors (Ob-R) coupling to 
the JAK-STAT (Janus kinase-signal transducers and activators of transcription) 
pathway of signal transduction (Hakansson and Meister 1998). The majority of both 
NPY/AGRP and POMC/CART neurons have been found to express Ob-Rs (Cheung 
et al. 1997; Baskin et al. 1999). STAT3 immunoreactivity has been shown in these 
neurons (Hakansson and Meister 1998). Both types of neurons are regulated by leptin 
but in opposite directions. Leptin inhibits NPY synthesis and release (Stephens et al. 
1995) and increases POMC mRNA expression (Schwartz et al. 1997). NPY neurons 
in the ARC are probably the primary targets mediating ghrelin-induced orexigenic 
effect. Ghrelin receptors have been identified on NPY neurons (Willesen et al. 1999). 
Peripheral administration of ghrelin induces Fos expression selectively in NPY 
neurons (Wang et al. 2002). 
From the arcuate ncl., NPY/AGRP and POMC/CART neurons project to 
"second order neurons" which are located in the PVN, VMH, DMH, and LHA. 
Several neuropeptides synthesized in PVN neurons reduce food intake and 
body weight when administered centrally. These include corticotropin-releasing 
hormone (CRH), also refered to as corticotropin-releasing factor (CRF), which causes 
anorexia and activates the sympathetic nervous system in addition to its role as a 
major regulator of the hypothalamic-pituitary-adrenal axis (Hotta et al. 1991); 
thyrotropin-releasing hormone (TRH), which reduces food intake in addition to 
stimulating the thyroid axis (Steward et al. 2003); and oxytocin, which reduces food 
intake (Verbalis et al. 1995) in addition to regulating uterine contractility (Ahn et al. 
2004), milk ejection (Wakerley et al. 1990), memory peocessing (Heinrichs et al. 
2004), social behavior (Keverne and Curley 2004) and autonomic functions (Mack et 
al. 2002). 
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The hypothesis that "second order neurons" involved in anabolic signaling 
reside within the LHA is supported by studies of melanin-concentrating hormone 
(MCH), an orexigenic peptide located in this brain area (Nahon 1994). Evidence that 
food consumption is increased by injection of MCH into the lateral ventricles of rats 
(Qu et al. 1996), and the discovery that MCH-knockout mice have reduced body 
weight and leanness due to hypophagia (Shimada et al. 1998) have suggested MCH as 
an orexigenic factor. Two additional peptides, termed hypocretin 1 and hypocretin 2 
(de Lecea et al. 1998), also named ‘orexin A and orexin B’ (Sakurai et al. 1998), are 
expressed exclusively in the LHA. These peptides increase food intake in addition to 
causing generalized behavioural arousal when administered centrally (Sakurai et al. 
1998; Hagan et al. 1999). The MCH gene is up-regulated in leptin-deficient ob/ob 
mice and leptin-insensitive db/db mice, whereas the orexin/hypocretin gene is down-
regulated in these mice (Qu et al. 1996; Yamamoto et al. 1999), indicating that the 
MCH and orexin systems are regulated through different pathways. 
The LHA is the most extensively interconnected area of the hypothalamus. 
Within the hypothalamus the lateral zone has reciprocal connections to the arcuate and 
paraventricular nuclei, and efferent projections to the dorsomedial, ventromedial and 
anterior hypothalamic nuclei. (Berthoud 2002). Rather than being passive recipients of 
information from the arcuate nucleus, these second order neurons process and transmit 
their input information via efferent projections to intrahypothalamic and 
extrahypothalamic sites. These include the hippocampal formation, extended 
amygdala, basal ganglia and thalamus, the midbrain and pons, the brain stem and 
spinal cord, allowing it to modulate many different functions from cognitive to 
autonomic. Most of the connections to brain stem and midbrain areas are reciprocal 
(Berthoud 2002). 
1.1.2 Feeding-related regions of the brain stem 
The brain stem is another important region in the brain to regulate food intake and 
body weight. All along the alimentary canal, various mechano- and chemosensors are 
located that transmit food and nutrition related signals via primary visceral afferents in 
the trigeminal (V), facial (VII), glossopharyngeal (IX), or vagus nerve (X) to the brain 
stem (Berthoud 2002). The gastrointestinal hormone cholecystokinin (CCK) is 
produced by mucosal enteroendocrine cells of the duodenum and jejunum and 
secreted in response to the presence of food within the gut lumen (Badman and Flier 
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2005). It contributes to the regulation of short-term food intake and is involved in the 
mediation of satiety (Glatzle et al. 2001). CCK activates neurons of the nucleus of the 
solitary tract (NTS) via stimulation of CCK-A receptors on vagal afferent nerve fibers 
supplying the gastrointestinal tract, which derive from the nodose ganglion, and have 
monosynaptic contact with NTS neurons (Raybould et al. 1988). Visceral primary 
afferent signaling is, however, not the only mode of communication between the gut 
and brain stem. Besides activating vagal afferent nerve fibers, circulating CCK may 
also act on CCK-A receptors in the area postrema (AP), a region of the brain stem that 
has a leaky blood-brain barrier and monosynaptic connection to the NTS (Glatzle et al. 
2001). 
The AP/NTS region of the brain stem plays an important role in the control of 
food intake (Hyde and Miselis 1983). This region receives nervous input from 
peripheral satiety signals via splanchnic and vagal afferents and hormonal input as 
well. Due to the lack of the blood brain barrier, receptors in this region can be reached 
directly by respective ligands circulating in the blood. The brainstem is sufficient for 
the integration of taste and gastrointestinal signals that co-determine the size of meals 
in the short term. However, if the brainstem is isolated from forebrain influences it is 
not sufficient for ingestive responses to systemic/metabolic signals that affect food 
intake over the long term (Grill and Kaplan 2001). The communication between 
hypothalamic pathways and the caudal brain stem, responding to meal-related satiety 
signals, is essential for the long-term regulation of energy homeostasis. 
1.2 Neuropeptides in the control of food intake and energy 
balance 
1.2.1 Orexigenic and anorexigenic peptides 
Over the past few years numerous novel signaling molecules, most of them, that affect 
food intake and that are critical for normal energy homeostasis have been identified 
when injected i.c.v. or in specific hypothalamic regions. These neuropeptides, listed in 
table 1, can be divided into orexigenic peptides which refer to molecules that promote 
increased energy intake, and anorexigenic peptides which cause the opposite. 
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Table 1 Neuropeptides implicated in the control of energy homeostasis 
Neuropeptide Treatment Food intake Reference 
Orexigenic    
NPY PVN injection ↑ (Stanley et al. 1986) 
AgRP CNS administration ↑ (Small et al. 2003) 
MCH i.c.v. injection ↑ (Qu et al. 1996) 
Orexin A i.c.v. administration ↑ (Haynes et al. 1999) 
Orexin B i.c.v. administration ↑/- (Edwards et al. 1999) 
Galanin PVN injection ↑ (Kyrkouli et al. 1990) 
Ghrelin i.c.v. injection ↑ (Nakazato et al. 2001) 
Anorexigenic    
α-MSH third ventricle administration ↓ (McMinn et al. 2000) 
β-MSH i.c.v. injection ↓ (Kask et al. 2000) 
CART i.c.v. injection ↓ (Kristensen et al. 1998) 
CRH i.c.v. administration ↓ (Hotta et al. 1991) 
TRH third ventricle administration ↓ (Steward et al. 2003) 
Oxytocin i.c.v. administration ↓ (Verbalis et al. 1995) 
Neurotensin i.c.v. administration ↓ (Luttinger et al. 1982) 
CCK Intraventricular administration ↓ (Figlewicz et al. 1989) 
GLP1 i.c.v. administration ↓ (Turton et al. 1996) 
Bombesin fourth ventricle administration ↓ (Ladenheim and Ritter 1988) 
Calcitonin third ventricle administration ↓ (Plata-Salaman and Oomura 
1987) 
Amylin third ventricle administration ↓ (Rushing et al. 2000) 
CGRP PVN injection ↓ (Dhillo et al. 2003) 
1.2.2 The calcitonin peptide superfamily 
Calcitonin, CGRP, and amylin, three members of the calcitonin peptide superfamily, 
are potent modulators of food intake (Poyner et al. 2002). Calcitonin (CT) was 
initially discovered in 1962 as a novel hypocalcemic hormone (Copp and Cheney 
1962), which is secreted from thyroid C-cells (Fischer and Born 1985). Tissue-
specific alternative RNA splicing of the calcitonin gene results in the production of 
distinct mRNAs encoding calcitonin or calcitonin gene-related peptide α (αCGRP). 
The brain-specific gene product of the calcitonin gene is αCGRP which is expressed 
in a number of brain areas involved in modulating ingestive behavior (Fischer and 
Born 1985). There is no evidence for the biosynthesis of calcitonin in the central 
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nervous system. Calcitonin and CGRP induce multiple biological effects including 
inhibition of food intake after peripheral and central administration (Plata-Salaman 
and Oomura 1987; Dhillo et al. 2003). 
The anorexigenic neuropeptide amylin, which is co-secreted with insulin from 
pancreatic islets β-cells in response to food ingestion (Butler et al. 1990) has been 
suggested as a physiological peripheral satiety agent to regulate short-term food intake 
(i.e., meal size) (Reidelberger et al. 2004). Recent studies have demonstrated that the 
AP/NTS region is involved in mediating the anorectic effect of amylin (Mollet et al. 
2004). There is a coincidental sensitivity (94%) of AP neurons to glucose and amylin, 
which exert excitatory effects on these cells. The co-sensitivity of AP neurons to 
glucose and amylin, both increasing in response to food intake, points to the AP as an 
important hindbrain center for the integration of the metabolic and hormonal control 
of nutrient intake (Riediger et al. 2002). Lesion experiments demonstrated that 
neurons in the AP/NTS region are necessary for chronically elevated peripheral 
amylin to reduce food intake in rats. High doses of amylin, however, may be able to 
bypass AP/NTS region and reduce feeding by acting at other brain sites (Lutz et al. 
2001). Feeding-induced amylin release activates AP neurons projecting to subsequent 
relay stations such as the NTS, the lateral parabrachial nucleus (LPBN) and the central 
nucleus of the amygdala (CeA) known to transmit meal-related signals to the 
forebrain. Activation of this pathway seems to coincide with an inhibition of LHA 
neurons (Riediger et al. 2004). However, the phenotype of these LHA neurons 
remains to be clarified. Although the effect of amylin on its primary target neurons in 
the AP has been well characterized, the involvement of higher brain centers, 
especially hypothalamic structures, is poorly understood. 
Amylin has also been suggested to serve as a satiety signal acting within the 
brain to regulate long-term energy homeostasis (Rushing et al. 2000; Rushing 2003). 
Intracerebroventricular (icv) infusion of low doses of amylin into the 3rd ventricle 
potently and dose-dependently reduced food intake and body weight and body 
adiposity of rat (Rushing et al. 2000), while infusion of a specific amylin antagonist 
(AC187) into the third ventricle significantly increased food intake (Rushing et al. 
2001). There is no evidence for amylin biosynthesis in the brain (Leffert et al. 1989). 
However, amylin immunoreactivity was found in brain areas including the 
hypothalamus (Skofitsch et al. 1995). Amylin can cross the blood-brain barrier 
suggesting that CNS amylin is derived from the circulation (Banks et al. 1995). 
8 
Introduction 
 
Binding sites for amylin are present in several brain regions including the nucleus 
accumbens, the area postrema, the nucleus of the solitary tract, the dorsal raphe, and 
the hypothalamus (Beaumont et al. 1993). The presence of amylin and its binding 
sites in discrete regions of the brain suggests that amylin might have a physiological 
function in the central nervous system.  
Amylin, like the other peptides of the calcitonin superfamily bind to specific 
receptor complexes, which consist of a G-protein coupled receptor, calcitonin (CT) 
receptor or calcitonin receptor-like receptor (CRLR), associated with different 
receptor-activity-modifying proteins (RAMPs) (Poyner et al. 2002). 
1.3 The calcitonin receptors 
Calcitonin receptors belong to the “family B” of seven transmembrane domain G-
protein-coupled receptors (7 TMD-GPCRs), which typically recognize regulatory 
peptides such as calcitonin (CT), parathyroid hormone (PTH), growth hormone 
releasing hormone, pituitary adenylate cyclase-activating peptide (PACAP), 
vasoactive intestinal peptide, glucagon, and glucagon-like polypeptide (Houssami et 
al. 1994). Binding of calcitonin (CT) to these receptors causes activation of membrane 
adenylyl cyclase (AC) and production of cAMP through the G protein Gs, promotion 
of polyphosphoinositide turnover and activation of protein kinase C (PKC) via G 
proteins of the Gq family; under certain conditions, CT inhibits AC via the Gi subclass 
of G proteins (Chakraborty et al. 1991; Chabre et al. 1992; Force et al. 1992; Orcel et 
al. 2000). 
The human calcitonin receptor was cloned in 1992 (Gorn et al. 1992). Multiple 
isoforms of the human calcitonin receptor have been described to be generated by 
differential RNA processing (Albrandt et al. 1995; Poyner et al. 2002). The best 
characterized splice variants of the human CT receptor gene differ by the presence 
(CT(b) receptor) or absence (CT(a) receptor) of 16 amino acids in the first intracellular 
loop. The human CT receptor isoforms have also been referred to as hCTR1 (CT(b)) 
and hCTR2 (CT(a)), respectively (Poyner et al. 2002). The two isoforms display 
similar ligand affinity. However, unlike the CT(a) receptor, the CT(b) receptor is poorly 
internalized and has altered coupling to G proteins. Loss of Gq-mediated responses 
and attenuation of Gs-mediated signaling has been observed upon stimulation of CT(b) 
receptor (Moore et al. 1995). 
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Two rat calcitonin receptor isoforms were identified in 1993 (Albrandt et al. 
1993; Sexton et al. 1993). Historically known as C1a and C1b receptor (Poyner et al. 
2002), they are now referred to as CT(a) and CT(b) according to the nomenclature 
recommendation of the IUPHAR (International Union of Pharmacology). The 
difference between the two isoforms is in the presence of a 111-bp insert in CT(b) 
corresponding to a 37-amino acid insert in the predicted second extracellular domain 
(Sexton et al. 1993). The functional consequence of this insertion is altered ligand-
binding kinetics and receptor specificity, but does not affect the ability of the receptor 
to couple to multiple intracellular signaling pathways (Houssami et al. 1994). 
An orphan receptor with 50 and 55% overall identity to the respective 
calcitonin receptors was identified in 1993 in rat (Njuki et al. 1993) and in 1995 in 
human (Fluhmann et al. 1995) and named calcitonin receptor-like receptor (CRLR). 
In 1998 it was identified as a specific receptor for CGRP or for adrenomedullin, 
depending on its association with distinct members of a new family of single 
transmembrane domain proteins, designated receptor-activity-modifying proteins 
(RAMPs) (McLatchie et al. 1998). 
1.4 Receptor-activity-modifying proteins 
The RAMP family of proteins comprises three members, RAMP1, RAMP2, and 
RAMP3. Rat RAMP1, RAMP2, and RAMP3 share 72%, 69% and 85% homology 
with their respective human homologues. RAMPs are required to transport GPCRs to 
the plasma membrane. This was first shown by McLatchie and coworkers for CRLR. 
RAMP1 enables CRLR to behave as a CGRP receptor. RAMP2 and RAMP3 are 
required for the CRLR to recognize adrenomedullin (AM) (McLatchie et al. 1998; 
Muff et al. 1998; Muff et al. 2001; Muff et al. 2003). 
The CT receptor does not require RAMP to bind and respond to calcitonin, but 
in association with RAMPs it can function as amylin or as CGRP receptor 
(Christopoulos et al. 1999; Muff et al. 1999). Detailed analysis of the receptor 
specificity of CTR/RAMPs has been performed mainly in in vitro systems 
(Tilakaratne et al. 2000). Several possible combinations between CT receptor variants 
and RAMPs exist. In vitro all three RAMPs will interact with CT(a) and CT(b) 
receptors to generate amylin receptors. The CT(b)/RAMP2 displays greater affinity to 
amylin than that of CT(a)/RAMP2 depending on the host cell environment (Tilakaratne 
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et al. 2000). The high affinity for rat amylin and markedly reduced affinity for 
αCGRP is characteristic for hCT(a)/RAMP3 (Christopoulos et al. 1999). Amylin 
receptors with varying affinity for CGRP have been observed in competition binding 
studies in rat brain (van Rossum et al. 1994). 
The possible combinations of the ligand-CT receptor/RAMPs complex are 
illustrated schematically in Fig. 2. 
 
Fig. 2 Schematic diagram of the ligand-CT receptor/RAMPs complex 
The calcitonin receptor does not require association with RAMPs in order to respond to calcitonin, but 
it can interact with RAMPs to form amylin and amylin/CGRP receptors (Modified after McLatchie et 
al. 1998). 
The distinct molecular complexes of the CT receptor and the RAMPs are 
known as AMY1, AMY2, and AMY3 receptors. Splice variants of the CT receptor 
can be accommodated in this scheme by use of letters: AMY1(a), AMY1(b), etc, (see 
table 2) (Poyner et al. 2002). Unknown tissue factors clearly play an important part in 
determining the pharmacological properties of any given CT receptor/RAMP 
combination. Thus, this classification may be subject to further refinement.  
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Table 2 Summary of nomenclature for the calcitonin receptor isoforms / RAMPs complex 
Molecular constituents Proposed nomenclature 
CT(a) + RAMP1 AMY1(a)
CT(a) + RAMP2 AMY2(a)
CT(a) + RAMP3 AMY3(a)
CT(b) + RAMP1 AMY1(b)
CT(b) + RAMP2 AMY2(b)
CT(b) + RAMP3 AMY3(b)
1.5 Distribution of rat calcitonin receptor isoforms 
Calcitonin receptors are found widely expressed in various tissues including 
osteoclasts, kidney, skeletal muscle, lung, placenta, primary breast cancers, and brain 
(Nicholson et al. 1986; Sexton et al. 1993; Lafond et al. 1994; Albrandt et al. 1995; 
Gillespie et al. 1997). 
Molecular studies using PCR revealed that CT(b) has a more restricted 
distribution, being primarily localized to the central nervous system, specifically the 
nucleus accumbens, hypothalamus, and brainstem, while the CT(a) isoform is more 
widely distributed (Sexton et al. 1993). Apart from the CNS, CT(a) is also expressed in 
the kidney (Sexton et al. 1993), skeletal muscle and lung (Albrandt et al. 1993). In 
vitro autoradiography demonstrated that brain regions displaying CT(a), but little or no 
CT(b), binding sites include the nucleus of the solitary tract and the area postrema. 
Nuclei expressing exclusively CT(b) receptors have not been identified yet (Hilton et al. 
1995). 
Immunohistochemistry was used to characterize the expression of CT 
receptors in rat brain at the protein level (Becskei et al. 2004). However, the 
antibodies employed could not distinguish between different CT isoforms. In situ 
hybridization was employed to demonstrate the expression of CT receptor genes in rat 
(Sheward et al. 1994; Tolcos et al. 2003; Barth et al. 2004) and mouse brain 
(Nakamoto et al. 2000). However, a detailed analysis of the pathway and neuron-
specific distribution of the CT(a) and CT(b) isoforms in specific brain structures and 
nuclei and in phenotype-identified neurons has not been performed. 
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1.6 Aims 
Since little is known on the pathway-specific expression and role of calcitonin 
receptors in the brain and its regulatory centers for food intake and energy expenditure, 
it was the main aim of this thesis to identify and compare the distribution of CT(a) and 
CT(b) isoforms and associated receptor complexes (RAMPs) in the rat brain with 
special emphasis on the feeding centers in the hypothalamus and brain stem and 
phenotype-identified neurons therein in order to characterize cellular and molecular 
mechanisms underlying CT-receptor mediated signaling in brain feeding pathways 
and beyond. The specific aims were the following: 
1. Comparison of gene expression of calcitonin receptor isoform expression in 
rat brain 
To determine the expression patterns of the CT(a) and CT(b) calcitonin receptor 
isoforms, their mRNA expression was investigated in specific brain structures and 
nuclei with particular focus on regions which are involved in the regulation of 
food intake and energy expenditure by employing RT-PCR, laser capture 
microdissection (LCM) in combination with RT-PCR, and in situ hybridization 
(ISH). 
2. Cell-specific expression of calcitonin receptor isoforms in phenotype-
identified hypothalamic and brain stem neurons involved in the regulation of 
food intake 
To elucidate whether CT receptor isoforms could play a role in the central 
regulation of food intake, their mRNA expression was investigated by dual in situ 
hybridization for coexistence with neuropeptides with proven relevance in the 
control of food intake. In the hypothalamus, NPY, POMC, CART, CRH, TRH, 
MCH and especially hypocretin/orexin neurons were tested for coexpression of 
CT receptor isoforms. In the area postrema, TRH neurons were characterized with 
respect to their content of CT receptor isoforms. This strategy should reveal the 
specific cellular sites of CT receptor function in relation to food intake. 
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3. Identification of CT receptor/RAMPs complexes in hypocretin/orexin 
neurons 
In order to further elucidate the possible functional significance of CT receptor 
isoforms in hypothalamic hypocretin/orexin neurons, these neurons were tested for 
their content of receptor-activity-modifying proteins (RAMP 1, 2, 3) in relation to 
CT receptor isoforms by dual in situ hybridization. 
4. Identification of CGRP terminals on orexin neurons 
Based on the hypothesis that CGRP could act as an endogenous ligand for CT 
receptors on orexin neurons, double immunohistochemistry for CGRP and orexin 
was performed to find out whether CGRP terminals target orexin neurons. 
5. Identification of classical neurotransmitters in orexin neurons 
To determine whether orexin neurons are glutamatergic or GABAergic, they were 
tested for co-expression with the vesicular glutamate transporter VGLUT2 as a 
marker of glutamatergic neurotransmission, and with the biosynthetic enzyme for 
the inhibitory neurotransmitter GABA, GAD67, as a marker for GABAergic 
neurotransmission, respectively. 
6. Pilot microarray analysis of differential gene expression in orexin neurons 
after fasting 
To identify novel candidate genes for the regulation of food intake in 
hypothalamic neurons suspected to express CT receptors, transcriptomic changes 
of orexin neurons after fasting were investigated by combining LCM with 
microarray analysis. Due to limitations of time and costs, validation of fasting-
induced gene regulation had to be apriori restricted to one newly identified 
candidate gene. Semi-quantitative in situ hybridization was envisaged as 
validation strategy to prove fasting-induced regulation of a chosen candidate gene. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Equipment  
β-γ Detector LB122 Berthold Amersham, Braunschweig 
Biofuge  Heraeus, Hanau 
Centrifuge 5403 Eppendorf, Hamburg 
CM 3050 Kryostat Leica, Nussloch 
DNA-Engine PTC-200 MJ Research, Watertown, USA 
Gene Amp PCR System 9700 Perkin Elmer, Foster City, USA 
Gel Doc 1000 BioRad, Hercules, USA 
HM 500 OM Kryostat Microm, Walldorf 
Hybridization oven Bachofer, Reutlingen 
MCID M5 Image analysis system Imaging Research, St. Catharines, Canada 
MicroPulserTM Electroporation Apparatus BioRad, Hercules, USA 
Microscope AX 70 Olympus Optical, Hamburg, Germany 
PixCell II Laser Capture Microdissection System Arcturus, San Diego, USA 
Power supply units BioRad, Hercules, USA 
Ultrospec 3000 UV/Visible Spectrophotometer Pharmacia, Freiburg 
Wallac 1410, Liquid Scintillation Counter Pharmacia, Freiburg 
Confocal Microscope Olympus Optical, Hamburg, Germany 
Hybridization Oven 640 Affymetrix, Santa Clara, USA 
Fluidics Station 400 Affymetrix, Santa Clara, USA 
GeneArray Scanner Affymetrix, Santa Clara, USA 
 
2.1.2 Chemicals and reagents 
Acetic acid Riedel-deHaёn, Seelze 
Acetic anhydride Sigma-Aldrich, Steinheim 
Acetylated Bovine Serum Albumin (BSA) 
solution (50 mg/ml) 
 
Invitrogen, Karlsruhe 
Agar Fluka, Buchs 
Agarose Invitrogen, Karlsruhe 
Albumin bovine Fraction V, pH7.0  Serva, Heidelberg 
Ammonium persulfate Serva, Heidelberg 
Ampicillin Sigma-Aldrich, Steinheim 
Antibiotic-Antimycotic (100 x) Invitrogen, Karlsruhe 
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5-bromo-4-chloro-3-indolyl-phosphate-4-
toluidine salt (BCIP) Roche, Mannheim 
Boric acid Merck, Darmstadt 
Bromphenol blue sodium salt Serva, Heidelberg 
Calcium Chloride Merck, Darmstadt 
Chloroform Roth, Karlsruhe 
Citric acid monohydrate Merck, Darmstadt 
Control Oligo B2, 3 nM Affymetrix, Santa Clara, USA 
Copper (II) acetate Merck, Darmstadt 
Cresyl violet acetate Fluka, Buchs 
D19 developer Kodak, New Haven, USA 
Denhardt’s Reagent (50 x) Sigma-Aldrich, Steinheim 
DePeX Serva, Heidelberg 
Deoxynucleoside triphosphate (dNTP) Roche, Mannheim 
Dextransulfate (Na-Salt) Fluka, Buchs 
3,3 diaminobenzidine tetrahydrochloride (DAB) Sigma-Aldrich, Steinheim 
Digoxigenin RNA Labeling Mix Roche, Mannheim 
Dimethylformamide Fluka, Buchs 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
Dithiothreitol (DTT) Roche, Mannheim 
Diethyl pyrocarbonate (DEPC) Roche, Mannheim 
Ethanol Riedel-deHaёn, Seelze 
Ethidium bromide Roth, Karlsruhe 
Ethylene diaminetetraacetic acid (EDTA) Merck, Darmstadt 
FluorSaveTM Reagent Calbiochem, San Diego 
Formamide Fluka, Buchs 
Formaldehyde, 37% Merck, Darmstadt 
GeneChip Eukaryotic Hybridization Control Kit 
(contains Control cRNA and Control Oligo B2) 
 
Affymetrix, Santa Clara, USA 
Glacial acetic acid Merck, Darmstadt 
Glycerol Merck, Darmstadt 
Glycine Roth, Karlsruhe 
Guanidine hydrochloride Roth, Karlsruhe 
Herring Sperm DNA Promega, Mannheim 
Hydrogen peroxide 30% H2O2 Merck, Darmstadt 
(2-Hydroxyethyl)-1-piperazineethanesulphonic 
acid (HEPES) Roth, Karlsruhe 
Isopropanol Merck, Darmstadt 
Isopentane (2-methyl butane) Fluka, Buchs 
Isopropylthio-β-D-galactoside (IPTG) Applichem, Darmstadt 
16 
Materials and Methods 
 
KAISER’S glycerol gelatin Merck, Darmstadt 
K5, Autoradiography emulsion Ilford, London, UK 
Ketanest 50 Parke-Davis, Freiburg 
Liquemin N 25000 (Heparin-Natrium) Roche, Mannheim 
β-mercaptoethanol Sigma, St. Louis 
MES Free Acid Monohydrate SigmaUltra Sigma-Aldrich, Steinheim 
MES Sodium Salt Sigma-Aldrich, Steinheim 
Methanol Merck, Darmstadt 
Na2-EDTA Merck, Darmstadt 
NaOH Merck, Darmstadt 
Natriumcitrate Dihydrate Merck, Darmstadt 
NBT (4-Nitroblue - Tetrazol - chloride ) Roche, Mannheim 
Nickel Fluka, Buchs 
NLS (normal lamb serum) GIBCO, Karlsruhe 
NorthernMax Pre/Hybridization Buffer Ambion, Austin, USA 
NTB2, Autoradiography emulsion Eastman Kodak, Rochester, NY 
NTP (nucleoside triphosphate) Roche, Mannheim 
Phenol/chloroform/isopropanol(25 : 24 : 1)  Roth, Karlsruhe 
Picric acid desensitized, contains 30% water Merck, Darmstadt 
RNase inhibitor MBI Fermentas, St.Leon-Rot, Germany 
Roenteroll, developer for X-ray film Tetenal, Norderstedt 
Rompun 2% Bayer, Leverkusen 
Rotiphorese Gel 30 Roth, Karlsruhe 
R-Phycoerythrin Streptavidin Molecular Probes 
SDS (Sodium dodecyl sulfate) Roth, Karlsruhe 
Sodium acetate Roth, Karlsruhe 
Sodium azide Merck, Darmstadt 
Sodium acetate Merck, Darmstadt 
Sodium chloride Merck, Darmstadt 
Sonicated salmon sperm DNA Invitrogen, Karlsruhe 
Superfix, Fixer for X-ray film Tetenal, Norderstedt 
TEMED, tetramethyl ethylene diamine Roth, Karlsruhe 
Tissue-Tek O.C.T compound Sakura, Zoetwerwounde, Netherlands 
Triethanolamine (TEA) Sigma-Aldrich, Steinheim 
3-(Triethoxysilyl) propylamine Merck, Darmstadt 
Tris (hydroxymethyl) aminomethane  Roth, Karlsruhe 
Triton X-100 Sigma-Aldrich, Steinheim 
TRIzol  Invitrogen, Karlsruhe 
tRNA Roche, Mannheim 
Tryptone Peptone DIFCO, Detroit, USA 
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Tween 20 Merck, Darmstadt 
X-gal peQLab, Erlangen 
Xylene Cyanole FF Sigma, St. Louis, USA 
Xylol Merck, Darmstadt 
Yeast extract DIFCO, Detroit, USA 
2.1.3 Buffers and solutions 
DEPC-treated H2O  
 10% (v/v) DEPC in ethanol was diluted in H2O to 0.1% (v/v). 
 incubated at 37°C overnight with shaking and autoclaved 
20 x SSC (pH 6.3-6.4)  
 3 M NaCl 
 0.3 M sodium citrate 
 By 1:10 dilution pH 7.05 
Denhardt´s reagent  
 1% (w/v) Ficoll 400 
 1% (w/v) polyvinylpyrrolidone 
 1% (w/v) bovine serum albumin 
10 x PBS (100 mM, pH 6.75):  
 1.53 M NaCl 
 77 mM Na2HPO4
 23 mM NaH2PO4
 by 1 x PBS (10 mM) pH 7.3-7.4 
50mM PBS (pH 7.45)  
 9.5 mM NaH2PO4
 40.5 mM Na2HPO4
 153 mM NaCl 
Bouin Hollande fixative solution   
Stock solution  
 25g copper (II) acetate dissolved in ddH2O 
 add 60g picric acid into the solution and dissolve it 
 add ddH2O to 1 L 
 filter, save in 4°C 
Working solution  
 100 part Bouin Hollande stock solution 
 10 part 37% formaldehyde 
 1 part acetic acid 
 prepare prior to use 
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10 mM Sodium citrate buffer (pH 6.0)  
Solution 1  
 0.1 M citric acid monohydrate 
Solution 2  
 0.1 M sodiumcitrate dihydrate 
 mix 54 ml solution 1 and 246 ml solution 2 
 add 2700 ml ddH2O to 3000 ml, pH 6.0 
ABC complex  
 1 drop (50 µl) solution A + 1 drop (50 µl) solution B 
 in 2.5 ml 1%BSA/PBS 
 preincubation for 30 min at RT prior to use 
DAB working solution  
 prepare DAB working solution prior to use: add 100 mg DAB in 800 ml 50 
mM PBS buffer 
 filter the solution into the vessel which is covered with tin foil 
Nickel enhancement  
 prepare Nickel enhancement prior to use: add 100 mg DAB and 600 mg Nickel 
sequentially in 800 ml 50 mM PBS buffer 
 mix completely  
 filter the solution into the vessel which is covered with tin foil 
TE buffer(pH 8.0)  
 10 mM Tris (pH 8.0), 
 1 mM EDTA (pH 8.0) 
TAE buffer(pH 8.0):  
 40 mM Tris-acetate 
 2 mM EDTA (pH 8.0) 
10 x HEPES-EDTA-buffer  
 200 mM HEPES (Sigma) 
 10 mM Na2-EDTA 
 pH 7.8, adjust with NaOH 
 filter and autoclave 
RNA sample buffer  
 1 ml 10 x HEPES-EDTA-Buffer 
 5 ml Formamide 
 1.6 ml 37% Formaldehyde 
RNA loading buffer  
 50% glycerol 
 0.5% Bromophenol blue 
 0.5% Xylene Cyanol 
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RNA gel electrophoresis buffer  
 1 x HEPES-EDTA-Buffer 
 6% Formaldehyde 
In situ hybridization buffer  
 600 mM NaCl 
 10 mM Tris-HCl pH 7.5 
 1 mM EDTA-Na2
 0.05% (w/v) tRNA 
 1 x Denhardt´s 
 10% (w/v) Dextransulphate 
 100 µg/ml Sonicated Salmon Sperm DNA 
 50% (v/v) Formamide 
 20 mM DTT 
Cresyl violet stain  
 0.5% cresyl violet 
 60 mM sodium acetate 
 340 mM acetic acid in ddH2O 
RNase buffer  
 10 mM Tris-HCl pH 8.0 
 0.5 M NaCl 
 1 mM EDTA 
 40 µg/ml RNase A (10 mg/ml in ddH2O stocking solution) 
 1 U/ml RNase T1 (500,000 U/ml stocking solution) 
  
4% phosphate-buffered Formaldehyde  
Solution 1  
 40 g (60 g) paraformaldehyde (PFA) 
 500 ml (750 ml) ddH2O (preheat water and cool to 50 - 55°C) 
 add concentrated NaOH slowly until solution clears 
Solution 2  
 100 ml (150 ml) 10 x PBS  
 400 ml (600 ml) ddH2O 
  
 mix both solutions together and cool to RT 
 adjust pH with concentrated HCl to 7.3 - 7.4 
 filter the solution and store at 4°C 
0.4% Triton X-100/PBS  
 prepare 0.4% Triton X-100 solution in 1 x PBS 
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TEA buffer (pH 8.0)  
 6.65 ml Triethanolamine 
 493 ml ddH2O 
 adjust the pH to 8.0 with HCl 
Digoxigenin detection buffers  
Buffer 1  
 100 mM Tris-HCl, pH 7.5 
 150 mM NaCl 
 dissolved in ddH2O 
Buffer 2  
 100 mM Tris-HCl, pH 9.5 
 100 mM NaCl 
 50 mM MgCl2
 dissolved in ddH2O 
Blocking buffer  
 10% NLS (normal lamb serum) 
 0.01% Triton X-100 
 dissolved in buffer 1 
Chromogen solution  
 10 ml buffer 2 
 45 µl NBT (4-Nitroblue-Tetrazol-chloride ) 
 35 µl BCIP (5-bromo-4-chloro-3- indolyl-phosphate ) 
  
12 x MES Stock (1.22 M MES, 0.89 M Na+)  
 70.4 g MES free acid monohydrate 
 193.3 g MES Sodium Salt 
 800 ml of molecular biology grade water 
 mix and adjust volume to 1000 ml 
 adjust pH to 6.5 - 6.7 
 filter through a 0.2 µm filter 
  
2 x Array hybridization buffer  
(Final 1 x concentration is 100 mM MES, 1 M Na+, 20mM EDTA, 0.01% Tween 20)  
 for 50 ml, add 
 8.3 ml of 12 x MES Stock 
 17.7 ml of 5 M NaCl 
 4.0 ml of 0.5 M EDTA 
 0.1 ml of 10% Tween 20 
 19.9 ml of water 
 store at 2°C to 8°C and shield from light 
21 
Materials and Methods 
 
20 x SSPE buffer  
 3 M NaCl 
 0.2 M NaH2PO4
 0.02 M EDTA 
  
Washing and staining buffers for microarray  
  Wash A: non-stringent wash buffer (6 x SSPE, 0.01% Tween 20)  
 for 1000 ml, add 
 300 ml of 20 x SSPE 
 1.0 ml of 10% Tween 20  
 699 ml of water 
 filter through a 0.2 µm filter 
  Wash B: stringent wash buffer (100 mM MES, 0.1 M Na+, 0.01% Tween 20)  
 for 1000 ml, add 
 83.3 ml of 12 x MES Stock Buffer 
 5.2 ml of 5 M NaCl 
 1.0 ml of 10% Tween 20 
 910.5 ml water 
 filter through a 0.2 µm filter 
 store at 2°C to 8°C and shield from light 
  2 x Staining buffer (Final 1 x concentration: 100 mM MES, 1 M Na+, 0.05% Tween 20)  
 for 250 ml, add 
 41.7 ml of 12 x MES Stock Buffer 
 92.5 ml of 5 M NaCl 
 2.5 ml of 10% Tween 20 
 113.3 ml water 
 filter through a 0.2 µm filter 
 store at 2°C to 8°C and shield from light 
  10 mg/ml goat IgG stock  
 resuspend 50 mg in 5 ml 150 mM NaCl 
 store at 4°C 
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2.1.4 Animals 
Wistar rats (200-225g, male) were purchased from Charles River (Sulzfeld, Germany).  
2.1.5 Radioactive nucleotides 
[α-35S] UTP (1000 Ci/mmol) Amersham Biosciences, Freiburg 
[α-35S] CTP (1000 Ci/mmol) Amersham Biosciences, Freiburg 
[α-35S] dATP (1000 Ci/mmol) Amersham Biosciences, Freiburg 
 
2.1.6 Kits 
ABC Kit Vectastain PK-6100 Vector, Burlingame, CA 
Advantage 2 PCR Kit BD Biosciences Clontech, USA
Avidin/Biotin Blocking Kit Vector, Burlingame, CA 
BioArrayTM HighYieldTM RNA Transcript 
Labeling Kit 
 
Affymetrix, Santa Clara, USA 
DIG Oligonucleotide Tailing Kit, 2nd Generation Roche, Mannheim 
GeneChip Sample Cleanup Module Affymetrix, Santa Clara, USA 
GeneChip T7-Oligo(dT) Promoter Primer Kit Affymetrix, Santa Clara, USA 
MessageAmpTM aRNA Kit Ambion, Austin, Texas, USA 
Poly(A)+ Tract mRNA Isolation System Promega, Mannheim 
QIAGEN Plasmid Maxi Kit QIAGEN, Hilden 
QIAprep Spin Miniprep Kit QIAGEN, Hilden 
QIAquick PCR Purifiation Kit QIAGEN, Hilden 
QIAquick Nucleotide Removal Kit QIAGEN, Hilden 
QIAquick Gel Extraction Kit QIAGEN, Hilden 
RNAqueousTM-Micro Kit Ambion, Austin, Texas, USA 
RNeasy Mini Kit QIAGEN, Hilden 
2.1.7 Enzymes 
AatII Roche, Mannheim 
AmpliTaq Gold DNA Polymerase Applied Biosystems, Darmstadt, Germany 
DNase I (RNase free) Roche, Mannheim 
E. coli DNA Ligase Invitrogen, Karlsruhe 
E. coli DNA Polymerase I Invitrogen, Karlsruhe 
E. coli Rnase H Invitrogen, Karlsruhe 
EcoRI New England Biolab, Schwalbach/Taunus 
HindIII New England Biolab, Schwalbach/Taunus 
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NcoI New England Biolab, Schwalbach/Taunus 
NdeI New England Biolab, Schwalbach/Taunus 
NotI New England Biolab, Schwalbach/Taunus 
PfuTurbo high fidelity DNA polymerase Stratagene, La Jolla, USA 
PstI New England Biolab, Schwalbach/Taunus 
RNA Polymerase (SP6, T7) Roche, Mannheim 
RNase A Roche, Mannheim 
RNase T1 Roche, Mannheim 
SacII New England Biolab, Schwalbach/Taunus 
SpeI New England Biolab, Schwalbach/Taunus 
SphI New England Biolab, Schwalbach/Taunus 
Superscript II Reverse Transcriptase Invitrogen, Karlsruhe  
Taq DNA polymerase Applied Biosystems, Foster City, USA 
T4 DNA Ligase Promega, Mannheim 
T4 DNA Polymerase Invitrogen, Karlsruhe 
XbaI New England Biolab, Schwalbach/Taunus 
2.1.8 Oligonucleotides 
The PCR primers were designed using the online program Primer 3 (http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). All oligonucleotides (see table 
3) were custom synthesized by MWG-Biotech (Ebersberg, Germany). The optimal 
annealing temperature was calculated using the primer analysis software Oligo 6 
(Molecular Biology Insights, West Cascade, USA). 
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Table 3 List of oligonucleotides 
Gene GenBank # Primer Name Sequence Annealing Tm Product size 
rCARTF63 ccctactgctgctgctacct 
CART NM_017110 
rCARTR741 cgggttatgatgtcatctgc 
56°C 698 bp 
rMCHF5 ccacttctccttcggcttta 
MCH M29712 
rMCHR683 tgcacaagtcaaagcatatca 
54°C 699 bp 
rorexinF19 tccttgggtatttggaccac 
orexin AF041241 
rorexinR511 gcgaggagaggggaaagtta 
59°C 512 bp 
rCT(a)F875 gtgcgacgggatcctataag 
rCT(a)R1125 gatgatgtaaagcaagtggg 
54°C 270 bp 
rCT(a)F643 caatgccttcactcctgaca 
CT(a) L14617 
rCT(a)R1603 cttcgttgttgctgactgga 
56°C 980 bp 
rCT(b)F723 gcatatttttcatcataacacat 
rCT(b)R811 atcacttcactgtcatgagggtc 
50°C 111 bp 
rCT(b)F474 caatgccttcactcctgaca 
CT(b) L13040 
rCT(b)R802 tcatgagggtccatctttcc 
54°C 348 bp 
rRAMP1F5 ctctgcttgccatggccctcggcctg 
RAMP1 AB030942 rRAMP1R435 ctacacgatgccctctgtgcgcttgctc 63°C 458 bp 
rRAMP2F15 caaggcgtgatggctccg 
RAMP2 AB030943 rRAMP2R552 ctacgcctgagcatcgccgtc 59°C 558 bp 
rRAMP3F10 ccatggcgaccccggcacag 
RAMP3 AB030944 
rRAMP3R476 cattcttctagcttgccaggcacg 
60°C 490 bp 
rGAPDHF119 cgaccccttcattgacctcaactacatg 
GAPDH AF106860 
rGAPDHR345 ccccggccttctccatggtggtgaagac 
59°C 227 bp 
2.1.9 DNA and RNA size markers 
1 kb DNA ladder GIBCO, Karlsruhe 
100 bp DNA ladder GIBCO, Karlsruhe 
1 kb DNA ladder MBI Fermentas, St.Leon-Rot, Germany 
100 bp DNA ladder MBI Fermentas, St.Leon-Rot, Germany 
2.1.10 Other supplies 
BioMax Film KODAK, USA 
CapSure LCM Transfer Film TF-100 Arcturus, San Diego, USA 
Electroporation Cuvette 1mm Peqlab Biotechnologie, Erlangen 
Eppendorf tubes Eppendorf, Hamburg 
Hyperfilm β-max Amersham Biosciences,Freiburg 
Hyperfilm MP Amersham Biosciences,Freiburg 
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Micro Bio-Spin P-30 Columns BioRad, Hercules, USA 
PAP-pen Beckman Coulter, France 
Tissue-Tek Cryomold Miles, Elkhart, USA 
Glass slides Menzel, Braunschweig, Germany 
2.2 Methods 
2.2.1 Animals 
Animal care and procedures were conducted according to institutional guidelines. All 
rats were housed in clean plastic cages and maintained on a 12 h-12 h light-dark cycle 
at room temperature 21 ± 1°C and had ad libitum access to food and water. 
For the fasting experiments, adult male Wistar rats (BW.200-225 g) were 
divided into two groups (n=3 per group). The control group rats had ad libitum access 
to food and water. The experiment group rats were fasted for 48h only with water 
available. After 48 h of fasting, the body weight of the rats was reduced in average 30 
± 4 g (n=3). 
2.2.2 Tissue preparation 
2.2.2.1 Coating of glass slides 
The glass slides were first washed with detergent at 60°C for 1 h with slightly shaking. 
The detergent was completely removed under running water. The slides were rinsed 
three times with deionized water. After 45 min washing in 70% ethanol with slightly 
shaking, the slides were dried by baking at 60°C. After immersion in 2% 3-
(Triethoxysilyl) propylamine in acetone for 30 sec, the slides were soaked 30 sec 
twice in acetone and twice in deionized water. Slides were then dried completely by 
baking overnight at 42°C.  
2.2.2.2 Paraffin sections 
2 Male Wistar rats were anesthetized with Ketamin (100mg/kg) and Rompun 
(10mg/kg) and perfused with 0.9% NaCl to wash the blood and with Bouin Hollande 
fixative solution to fix the tissue. Brains were removed and cut into forebrain, 
midbrain and hindbrain and immersed into the same fixative solution for 24-48 h with 
slightly shaking, then rinsed in 70% 2-propanol. Alcohol was changed daily until the 
fixative was completely washed out. After standard dehydration, brains were 
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embedded in paraffin, 7 µm sections were cut through hypothalamus. The sections 
were mounted on adhesive slides and stored at room temperature. 
2.2.2.3 Frozen sections 
The rats were killed by exposure to 100% CO2. Brains were rapidly removed and 
embedded in Tissue-Tek OCT compound (Sakura, Zoeterwoude, The Netherlands) by 
immersion in -50°C cold 2-Methylbutane (Fluka, Seelze, Germany) on dry ice for 
cutting. For in situ hybridization histochemistry, 14µm thick serial coronal rat brain 
sections were cut on a Leica Cryostat (Leica) and thaw-mounted on adhesive slides 
and stored at -70°C. For laser capture microdissection, 10µm coronal sections were 
cut and mounted on non-coated glass slides and stored at -70°C. 
2.2.3 Immunocytochemistry 
2.2.3.1 Double sequential immunostaining 
Double sequential immunostaining was performed on deparaffinized paraffin-
embedded tissue sections (7 µm) using standard avidin-biotin-peroxidase techniques 
(Vectastain Elite ABC kit, Boehringer). For optimal antigen retrieval, sections were 
incubated in a pressure cooker (15 min at 95°C in 10 mM Na-citrate buffer, pH 6.0) 
and blocked by successive 30 min incubation in 5% bovine serum albumin (BSA) and 
avidin-biotin-blocking kit (Vectastain Elite, Boehringer). Orexin neurons were 
visualized with a goat-anti-rat polyclonal antibody against orexin A diluted 1:8000. 
Primary antibodies were applied in 1% BSA/PBS and incubated at 16°C overnight 
and at 37°C 2 h. Sections were washed and incubated with 1:200 donkey-anti-goat 
biotinylated secondary antibody (Dianova, Hamburg) for 45 min at 37°C. 
Immunoreactions were visualized with 3,3’-diaminobenzidine, resulting in a brown 
staining. 
For CGRP double staining, after dehydration through a graded series of 2-
propanol and in methanol/H2O2 solution for 30 min treatment, sections were 
rehydrated in a gradient series of 2-propanol and blocked with BSA and the avidin-
biotin reagents to block potential nonspecific binding of the second avidin-biotin-
peroxidase complex to the first avidin-biotin-peroxidase complex. CGRP was 
visualized with a rabbit-anti-rat polyclonal antibody against CGRP diluted 1:120.000. 
Primary antibodies were applied in 1% BSA/PBS and incubated at 16°C overnight 
and at 37°C 2 h. Sections were washed and incubated with 1:200 donkey-anti-rabbit 
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biotinylated secondary antibody (Dianova, Hamburg) for 45 min at 37°C. The second 
primary antibody was visualized by DAB/peroxidase reaction enhanced by the 
addition of 0.08% ammonium nickel sulfate resulting in a dark blue staining. After 
dehydration procedure, slides were covered with DepeX. 
2.2.3.2 Double immunofluorescence 
For simultaneous detection of orexin and CGRP hypothalamic sections were 
incubated overnight at 16°C and 2 h at 37°C with goat-anti-rat orexin A antibody 
diluted 1:800 together with rabbit-anti-rat CGRP antibody diluted 1:10000. Sections 
were incubated with 1:200 donkey-anti-rabbit biotinylated secondary antibody 
(Dianova, Hamburg) which interacted with the rabbit-anti-rat CGRP antibody for 45 
min at 37°C, then further incubated with the mixture of 1:200 donkey-anti-goat A647 
(Molecular probes, Leiden, The Netherlands) together with 1:200 Alexa A488-
conjugated streptavidin (Molecular probes, Leiden, The Netherlands) for 2 h at 37°C 
to detect the signals of orexin A and CGRP. After 3 x 5 min washes in ddH2O, 10 min 
washes in PBS, slides were covered with FluorSaveTM Reagent. 
Table 4 List of primary antibodies 
Antigen Dilution Species Source/Reference 
Orexin A 1:8000a / 1:800b Goat polycl. Santa Cruz, California 
CGRP 1:120000a / 1:10000b Rabbit polycl. (Rohrenbeck et al. 1999) 
adilution for enzymatic sequential immunostaining, bdilution for immunofluorescence 
2.2.4 Laser capture microdissection (LCM) 
2.2.4.1 Microdissection of orexin neurons 
Frozen sections were rapidly transferred from -70°C without drying and fixed in 4% 
paraformaldehyde/PBS for 2h. Then sections were blocked by successive 30 min 
incubations in 5% bovine serum albumin (BSA) and avidin-biotin-blocking kit 
(Vectastain Elite, Boehringer). Orexin neurons were visualized with a goat-anti-rat 
polyclonal antibody (1:800) against orexin A (Santa Cruz, California). Primary 
antibodies were applied in 1% BSA/PBS and incubated at 16°C overnight and at 37°C 
2 h. Sections were washed and incubated with 1:100 indocarbocyanine (Cy3)-
conjugated antigoat secondary antibody (Dianova, Hamburg) at 37°C 2h, resulting in 
a red-orange fluorescence labeling. RNase inhibitor (40U/µl, MBI Fermentas, St. 
Leon-Rot, Germany) was added to the blocking buffers and the antibody solutions 
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(80U RNase inhibitor /ml buffer). After dehydration procedure, sections were air-
dried. 
Immunofluorescent labeled orexin neurons were microdissected using the 
laser capture microdissector (Arcturus Inc., San Diego) with CapSureTM LCM 
Transfer Film TF-100 caps. The following settings were used: 7.5 µm laser spot size, 
65 mW pulse power, 1.2 ms pulse width, 10mV threshold voltage. After capturing, 
the caps were plugged into the 0.5 ml plastic tubes (Eppendorf, Köln, Germany) 
containing 100µl lysis buffer from RNAqueousTM Micro Kit (Ambion). The tubes 
were vortexed in an inverted position for 30 sec. The samples were collected by 
centrifugation. 
2.2.4.2 Microdissection of the area postrema (AP) and of the nucleus of the solitary 
tract (NTS) 
At the day of microdissection, frozen slides were rapidly transferred from -70°C 
without drying and put into 95% ethanol, 75% ethanol and 50% ethanol each for 5-7 
quick dips through pre-staining fixation steps, then in 1% cresyl violet acetate made in 
100% ethanol for 5min staining. The post-staining steps were 50% ethanol, 75% 
ethanol and 95% ethanol each 5-7 quick dips, 100% ethanol 30sec, two times xylene 
each 5min. Sections were air dried completely.  
AP and NTS were microdissected from cresyl violet acetate stained sections 
using the laser capture microdissector (Arcturus Inc., San Diego) with CapSureTM 
LCM Transfer Film TF-100 caps using the following settings: 30 µm laser spot size, 
80 mW pulse power, 4.0 ms pulse width, 90mV threshold voltage. After capturing, 
the caps were plugged into the 0.5ml plastic tubes (Eppendorf, Köln, Germany) 
containing 100µl lysis buffer from RNAqueousTM Micro Kit (Ambion). The tubes 
were vortexed in an inverted position for 30 sec. The samples were collected by 
centrifugation. 
2.2.5 RNA isolation 
Total RNA from different tissues was isolated using TRIzol Reagent (Invitrogen) 
according to the manufacturer’s protocol. RNA from 320 microdissected orexin 
neurons and from AP and NTS of 5 sections were isolated using RNAqueousTM Micro 
Kit (Ambion) according to the manufacturer’s protocol. RNA samples were treated 
with DNase I (Roche) for 30 min at 37°C and then purified with RNeasy Mini Kit 
(QIAGEN). 
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2.2.6 Reverse transcriptase polymerase chain reaction (RT-PCR) 
2.2.6.1 Complementary DNA (cDNA) synthesis 
cDNA was synthesized using Superscript II RNase H- reverse transcriptase 
(Invitrogen) in total volume of 20 µl. DNase I treated total RNA from different tissues 
was incubated with oligo(dT) 12-18 (1.25 µM, Amersham Pharmacia Biotech, 
Freiburg, Germany) at 70°C for 10 min in a volume of 11 µl and chilled on ice for 2 
min. The reaction was performed in the presence of dithiothreitol (DTT) (10 mM), 
reverse transcriptase (200 U), dNTPs (500 µM), the first strand buffer (Invitrogen) 
and incubated at 16°C for 10 min, at 42°C for 1 h and at 94°C for 5 min to inactivate 
the enzyme. For mock reactions the Superscript II RNase H- reverse transcriptase was 
omitted. The cDNA was diluted to 50 µl by adding 30 µl PCR grade water and stored 
at –20°C. 
2.2.6.2 Polymerase chain reaction (PCR) 
All PCR reactions were performed on a GeneAmp 9700 cycler or PTC-200 cycler. 
For PCR amplification of rat CT(a) and CT(b) the following gene specific primers were 
used: rat CT(a) (Genebank Accession No. L14617, nt. 875-1144, 270bp), forward 
primer: gtgcgacgggatcctataag, reverse primer: gatgatgtaaagcaagtggg; rat CT(b) 
(Genebank Accession No. L13040, nt. 474-821, 348bp), forward primer: 
caatgccttcactcctgaca, reverse primer: tcatgagggtccatctttcc. Hot start PCR was 
performed using 5µl cDNA in a total volume of 50µl containing 1x PCR buffer, 3mM 
MgCl2, 200µM dNTPs mixture, 0.2µM primers mixture and 1U AmpliTaq GoldTM 
(Applied Biosystems, Darmstadt, Germany) with the following program: 1 cycle  
95°C 10 min, 10 cycles (94°C 30sec, 59°C 30sec/ -0.5°C per cycle , 72°C 30sec), 40 
cycles (94°C 30sec, 54°C 30sec, 72°C 30sec) and 10 min extension at 72°C. As 
positive control glyceraldehydes phosphate dehydrogenase (GAPDH) was used as 
house keeping gene yielded a 227 bp PCR product (AF106860, nt. 119 – 345). 
Negative controls included RNA subjected to RT-PCR without reverse transcriptase, 
and PCR with water replacing cDNA. PCR products of 10 µl from each reaction were 
loaded and separated on 1.5% agarose gel containing ethidium bromide (EtBr). The 
gels were visualized under an ultraviolet transilluminator (BioRad). The PCR 
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products were subcloned and sequenced. The sequence identity of the PCR products 
was confirmed by comparison with the published sequences in Genebank. 
2.2.7 Agarose gel electrophoresis 
To separate DNA fragments in a size range of 100 to 10.000 bp 1.5% agarose gel was 
routinely used (Sambrook and Russell 2001). The appropriate amount of agarose was 
dissolved in 1 × TAE buffer by boiling for a few minutes in a microwave oven. When 
the gel solution had cooled down to about 60°C, ethidium bromide was added to a 
final concentration of 0.5 µg/ml. The solution was then poured into a gel mold. 
Suitable combs were used for generating the sample wells. The gel was allowed to 
harden for some 30 - 45 min. The gel was mounted in the electrophoresis chamber 
which was filled with 1 x TAE running buffer until the gel was just submerged. DNA 
samples and size standards were mixed with 0.1 volumes of 10 × loading buffer and 
applied to the wells. A voltage of 2 - 10 V/cm was applied until the bromophenol blue 
and xylene cyanol FF dyes had migrated the appropriate distance through the gel. 
After completion of electrophoresis gels were examined under UV transilluminator 
and photographed using a gel documentation system (BioRad). 
2.2.8 Cloning 
The QIAquick PCR Purification Kit (QIAGEN) was used to purify PCR products. 
The purified PCR fragments of rCART, rMCH, rNPY, rorexin, rVGLUT2, rGAD, 
rCT(a), rCT(b), rRAMP1, rRAMP2, rRAMP3 and rGAPDH were ligated into pGEM-T 
Vector (Promega), the fragment of rCRH was ligated into pGEM-3Z (Promega), the 
fragments of rPOMC and rTRHR2 were ligated into pcDNA3.1(+) (Invitrogen) and 
the fragments of rTRH and rTRHR1 were ligated into pBluescript II KS(+) 
(STRATAGENE). The plasmid constructs were electroporated into XL1-Blue of E. 
coli electrocompetent cells using MicroPulserTM Electroporation Apparatus (BioRad) 
according to manufacturer’s instruction. The positive clones were amplified and the 
plasmids were isolated from the cells by using QIAfilter Plasmid Maxi Kit (QIAGEN) 
and sequenced in Sequence Laboratories (Goettingen) with universal primers T7, SP6, 
T3 and gene specific primers. Sequences were then confirmed by homology search 
using BLAST 2.0 (http://www.ncbi.nlm.nih.gov). The plasmids were linearized by 
different restriction enzymes as shown in table below. RNA polymerases using to 
produce sense or antisense RNA probes were indicated. 
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Table 5 List of plasmids 
Gene Insert Enzyme Probe RNA polymerase 
NdeI sense T7 
rCART 698 bp 
NcoI antisense SP6 
NcoI sense SP6 
rNPY 440 bp 
NdeI antisense T7 
HindIII sense SP6 
rPOMC 433 bp 
XbaI antisense T7 
NotI sense T7 
rMCH 699 bp 
NcoI antisense SP6 
SphI sense SP6 
rOrexin 512 bp 
NdeI antisense T7 
HindIII sense T7 
rTRH 800 bp 
EcoRI antisense T3 
EcoRI sense SP6 
rCRH 770 bp 
HindIII antisense T7 
SpeI sense T7 
rVGLUT2* 1060 bp 
NcoI antisense SP6 
 sense T7 
rGAD* 841 bp 
 antisense SP6 
NotI sense T7 
rCT(a) 980 bp AatII antisense SP6 
NdeI sense T7 
rCT(b) 111 bp NcoI antisense SP6 
SpeI sense T7 
rRAMP1 458 bp 
SphI antisense SP6 
SpeI sense T7 
rRAMP2 558 bp 
SphI antisense SP6 
SpeI sense T7 
rRAMP3 490 bp 
SphI antisense SP6 
EcoRI sense T3 
rTRHR1* 549 bp 
HindIII antisense T7 
XbaI sense T7 
rTRHR2* 1308 bp 
HindIII antisense SP6 
SalI sense T7 
rGAPDH* 227 bp 
ApaI antisense SP6 
*Plasmids for rVGLUT2, rGAD and rGAPDH were previously generated in the laboratory; plasmids 
for rTRHR1 and rTRHR2 were kindly provided by K. Bauer (Heuer et al. 2000).  
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2.2.9 Probes 
2.2.9.1 Complementary RNA probes 
In vitro transcription reactions were performed to prepare the complementary RNA 
probes. For preparing the GAD probes, PCR product template was prepared from the 
plasmid construct with T7 and SP6 primers. For preparing the other probes, plasmids 
containing the specific gene fragments were linearized by different restriction 
enzymes. In vitro transcription reactions were carried out in a volume of 10 µl 
contained 1 µg linearized plasmids or PCR product, 10 mM DTT (GibcoBRL), 20 U 
RNase inhibitor (MBI Fermentas, St.Leon-Rot, Germany), 1 x In vitro transcription 
buffer, 20 U RNA polymerase (Roche), 0.5 mM NTPs mixture with 35S-UTP or both 
35S-UTP and 35S-CTP (>1000 Ci/mmol, Amersham Pharmacia Biotech, Freiburg, 
Germany) or 1 x DIG Labeling RNA Mix with digoxigenin-11-UTP (Roche). After 
90 min incubation at 37°C, 10 U RNase-free DNase I (Roche) was added into the 
reactions and incubated for another 15 min. After adding RNase-free water to 20 µl 
and 20 µl sodium carbonate buffer (pH 10.2, 80 mM NaHCO3 – 120 mM Na2CO3) for 
limited hydrolysis, the reactions were incubated at 60°C for the appropriate time [t = 
(Lo – Lf)/ K* Lo * Lf, Lo: the cDNA length, Lf: expected length of the probes (it is 
250 bp in our laboratory), K is 0.11 in our case] (Schafer et al. 1993; Schafer and Day 
1995). The reactions were stopped by adding 2 µl 10% acetic acid. 28 µl RNase-free 
water was added and probes were purified using Micro Bio-Spin P-30 columns 
(BioRad). 
2.2.9.2 Oligonucleotide probes 
The oligonucleotide sequence of orexin, 5’-gccgctttcccagagtgaggatgcccgcggcgtggttgc 
cagctccgt-3’ (Genebank Accession No. NM_013179, nt. 248-295, 48bp) was selected 
using the online program Primer 3 (http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi) considering the parameters of melting temperature, GC 
content, length, hairpins and length of runs and synthesized by MWG-Biotech 
(Ebersberg, Germany). 
The design of a specific oligonucleotide probe for CT(a) mRNA was 
complicated by the fact that CT(a) mRNA differs from CT(b) only by the 111bp insert 
representing the alternatively spliced exon 9 (see Fig. 4). Thus, the specific 
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oligonucleotide probe was designed to bind to the CT(a) mRNA region bridging exon 
8 and exon 10, but it had to be short enough making it unable to form a stable hybrid 
with only exon 8 or only exon 10 at the hybridization temperature. The 
oligonucleotide sequence of CT(a) is 5’-aaaaagtgcagaatcttgcaacttataggatcccgtcgcaccag 
gtct-3’ (Genebank Accession No. L14617, nt. 868-915, 48bp).
For the [α-35S]dATP labelling of the oligonucleotide probe, the Reaction Mix 
was prepared by adding the following reagents: 25.5 µl ddH2O, 7.2 µl oligonucleotide 
(0.72 pmol/µl), 10 µl of 5 x terminal transferase buffer (Roche), 3 µl of 25 mM CoCl2 
(Roche), 4 µl of 10 mCi/ml [α-35S]dATP (40 µCi) (Amersham) and 0.3 µl of 400 
U/µl Terminal Transferase (120 U) (Roche), total reaction volume was 50 µl. The 
reaction was incubated for 20 min in 37°C water bath, thereafter placed on ice. 400 µl 
TE buffer and 2.5 µl of 20 µg/µl yeast-tRNA were added to the reaction mixture and 
mixed thoroughly. The labeled probe was extracted with 0.5 volume of saturated 
phenol and 0.5 volume of chloroform/isoamyl-alcohol (49:1), vortexed and 
centrifuged for 5 min at 11000 rpm. The upper phase was transferred to a new tube 
and washed with 1 volume of chloroform/isoamyl-alcohol (49:1) and centrifuged for 5 
min at 11000 rpm. The upper phase was transferred again in another new tube. The 
labeled probe was precipitated with 20 µl of ice-cold 5 M NaCl and 2 volume of cold 
(-20°C) absolute ethanol. The tube was kept at -70°C for at least 30 min and 
centrifuged for 30 min at 11000 rpm. The pellet was rinsed with 500 µl of 70% cold (-
20°C) ethanol and air dried and resuspended in 50 µl TE buffer containing 10 mM 
DTT. The incorporated radioactivity was measured in a liquid scintillation counter. 
Digoxigenin-labeling of the oligonucleotide probe was prepared with DIG 
Oligonucleotide Tailing Kit, 2nd Generation (Roche) according to the manufacturer’s 
protocol. the Reaction Mix was prepared by adding the following reagents: 100 pmol 
oligonucleotide in 9 µl, 4 µl of 5 x reaction buffer, 4 µl of 25 mM CoCl2, 1 µl of 1 
mM DIG-11-dUTP, 1 µl of 10 mM dATP and 1 µl of 400 U/µl terminal transferase 
(400 U), total reaction volume was 20 µl. The reaction was incubated for 15 min in 
37°C water bath, thereafter placed on ice. 2 µl of 0.2 M EDTA (pH 8.0) was added to 
stop the reaction. 
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2.2.10 In situ hybridization (ISH) 
2.2.10.1 Prehybridization 
Frozen sections were removed from the freezer and air dried at room temperature for 
15 min and fixed in 4°C pre-cooled 4% paraformaldehyde in phosphate-buffered-
saline (PBS) for 60 min at room temperature. After three washes in 10 mM PBS (pH 
7.4) for 10 min each and incubation in 0.4% Triton X-100 for 10 min, the slides were 
rinsed in deionized water and transferred to 0.1 M triethanolamine (pH 8.0) (Sigma). 
After incubation for 1 min, acetic anhydride (Sigma) was added under strong stirring 
to a final concentration of 0.25% (v/v) and further incubated for 10 min. The slides 
were washed for 10 min in 10 mM PBS (pH 7.4) and rinsed in deionized water prior 
to dehydration in 50% and 70% isopropanol. Finally, the slides were air-dried at room 
temperature for 15 min and stored at -20°C. 
2.2.10.2 Hybridization 
For RNA probes, in situ hybridization was performed as described previously 
(Schafer et al. 1993; Schafer and Day 1995), Briefly, the frozen prehybridized 
sections were air dried and marked. The radioactive probes were diluted to 5 x 104 
dpm/µl (single radioactive labeling) or 1 x 105 dpm/µl (double radioactive labeling) in 
ISH buffer. Appropriate amounts of hybridization solution containing radioactive 
antisense or sense RNA probes were applied to the sections. Slides were coverslipped 
and incubated at 60°C in humid box containing 50% formamide for 16 h. Sense 
probes were used as nonspecific controls. 
For oligonucleotide probes, the radiolabeled oligonucleotides were diluted to 4 
x 104 dpm/µl in ISH buffer. Appropriate amounts of hybridization solution were 
applied to the sections. Slides were coverslipped and incubated at 42°C in humid box 
containing 50% formamide for 16 h. 
2.2.10.3 Posthybridization 
For posthybridization of sections hybridized with RNA probes, coverslips were 
removed by dipping in 2 x SSC and slides were washed in 2 x SSC and 1 x SSC for 
20 min each at room temperature followed by incubation in pre-heated to 37°C RNase 
buffer (10 mM Tris-HCl pH 8.0, 0.5 M NaCl, 1 mM EDTA) containing 1 U/ml RNase 
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T1 and 40 µg/ml RNase A (Roche) for 30 min at 37°C and 30 min at room 
temperature with stirring. Slides were washed at room temperature in 1 x, 0.5 x, and 
0.2 x SSC for 20 min each, at 60°C in 0.2 x SSC for 60 min and at room temperature 
in 0.2 x SSC and deionized water for 15 min each. The tissue was dehydrated in 50% 
and 70% isopropanol and then air-dried. 
For posthybridization of sections hybridized with oligonucleotide probes, 
coverslips were removed by dipping in pre-warmed to 55°C 2 x SSC and slides were 
washed in 55°C 1 x SSC for 4 times, each 15 min, in room temperature 1 x SSC for 1 
h and in ddH2O for 1 min. The tissue was dehydrated in 50% and 70% isopropanol 
and then air-dired. 
2.2.10.4 Detection 
Air-dried hybridized slides were exposed to Kodak BioMax MR Film (Amersham) for 
an appropriate period of time. After exposure to X-ray film, the sections were coated 
with nuclear emulsion NTB-2 (Eastman Kodak, Rochester, NY). The coated slides 
were dried overnight in a dark box in the dark room. The dried slides were exposed 
for 3 to 42 days at 4°C. The slides were developed for 4 min in Kodak D-19 developer 
solution and fixed for 10 min in Tetenal Superfix25 solution (Tetenal Photowerk, 
Norderstedt, Germany) at room temperature. The developed slides were washed 
overnight in running tap water. After staining with 0.5% cresyl violet for 15 min, the 
slides were washed in deionized water for 3 min, once in 70% and 96% and twice in 
100% isopropanol alcohol for 2 min each. After final incubation in Xylol twice for 5 
min, the sections were coated with DePex and covered with glass coverslips. The 
sections were analyzed under an Olympus AX70 microscope (Olympus) and 
photographed under bright or dark field illumination. 
2.2.10.5 Double in situ hybridization 
For double ISH the digoxigenin labeled RNA probes were added to a final 
concentration of 0.5 ng/µl in the hybridization solution containing radioactive RNA 
probes and digoxigenin labeled oligonucleotide probes were added to 1:200 in the 
hybridization solution containing radioactive oligonucleotide probes. Hybridization 
and washing procedures were the same as described above except dehydration in 
alcohol was omitted. For the detection of non-radioactive hybrids, the slides were 
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incubated for 1 h with blocking-buffer (buffer 1 containing 10% normal lamb serum, 
0.01% Triton X-100). After rinsing in buffer 1, the slides were incubated with 1:1000 
diluted antibody (alkaline phosphatase-conjugated anti-DIG Fab fragments in 1:10 
diluted blocking buffer by buffer 1) overnight at 4°C and 1 h at 37°C. Excessive 
antibody was removed by washing in buffer 1 for 10 min twice. Slides were 
equilibrated in buffer 2 (100 mM Tris-HCl, pH 9.5, 100 mM NaCl; 50 mM MgCl2) 
prior to color reaction. The color reaction was performed using the solution containing 
5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium salt (NBT) 
(Roche). The color development was controlled under the microscope. After 20 min 
for MCH and orexin, 1 h for TRH and 2 h for CART, slides were washed in deionized 
water for at least one day with several changes. For detection of 
35
S-labeled probes, 
the slides were dipped in K5 Emulsion (ILFORD Imaging, Mobberley Chershire, UK), 
which was diluted 1: 1 in water. Sections were exposed at 4°C for various times. The 
cellular distribution of silver grains of radioactive probes and the violet precipitate of 
DIG probes was studied under an AX70 light microscope (Olympus). 
2.2.11 Grain counting analysis 
Computer-aided grain counting was performed on autoradiograms using the 
microcomputer imaging device (MCID) image analysis software (Imaging Research 
Inc, St. Catharines, Ontario, Canada). The animals were divided into two groups, one 
control group and one 48 h fasted group. From three animals per group 9 sections per 
animal were used for grain counting analysis. The perikarya with a nucleus of each 
labeled orexin neurons was scanned (scan area) and silver grains were counted. 
Background labeling was determined in sections hybridized with the sense probes. 
The background labeling ranged from 2 to 7 grains per orexin perikarya. 
Measurements were expressed as the number of grains per cell and the grain density 
(grains per 100 µm2 scan area). Differences between groups were analyzed using 
Statview 5.0 software program (SAS Institute Inc.). p values < 0.05 were considered 
statistically significant. 
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2.2.12 Microarray analysis 
Gene expression of orexin neurons from control and fasted rats was compared using 
microarray analysis according to Affymetrix GeneChip Expression Analysis 
Technical Manual. 
The Affymetrix GeneChip probe arrays are manufactured using technology 
that combines photolithography and combinatorial chemistry. Each oligonucleotide is 
located in a specific area on the array called a probe cell. Each probe cell contains 
hundreds of thousands to millions of copies of a given oligonucleotide. Biotin-labeled 
cRNA targets derived from the mRNA of an experimental sample are hybridized to 
nucleic acid probes attached to the solid support. The hybridized probe array is 
stained with streptavidin phycoerythrin conjugate and scanned by the GeneArray® 
Scanner. The amount of light emitted at 570 nm is proportional to the bound target at 
each location on the probe array. By monitoring the amount of label associated with 
each DNA location, it is possible to infer the abundance of each mRNA species 
represented (See www.affymetrix.com for current GeneChip technology references). 
In the present study, GeneChip® Rat Expression 230A Array was used to 
analysis the regulation of gene expression associated with food intake in orexin 
neurons. The Rat 230A Array contains primarily probe sets against 5399 genes and 
10467 ESTs. 
The following major steps outline GeneChip expression analysis: target 
preparation, target hybridization, probe array washing, staining and scanning, data 
analysis. 
2.2.12.1 Target preparation 
2.2.12.1.1 RNA isolation from microdissected orexin neurons 
A series of 10µm thick frozen brain sections from 3 fasted rats and from 3 control rats 
were used for LCM. After immunofluorescence staining, the orexin neurons were 
microdissected. Total RNA was isolated from the microdissected orexin neurons 
using RNAqueousTM Micro Kit (Ambion) according to the manufacturer’s protocol 
and treated with DNase I (Roche) for 30 min at 37°C. Followed the purification using 
RNeasy Mini Kit (QIAGEN), the RNA samples were precipitated with ethanol and 
resuspended in appropriate volume of nuclease-free water for RNA amplification. 
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2.2.12.1.2 First round RNA amplification 
The first round RNA amplification was performed using MessageAmpTM aRNA Kit 
(Ambion) according to the manufacturer’s protocol. For the first strand cDNA 
synthesis, 1 µl of T7 Oligo(dT) Primer was added to the RNA sample, the nuclease-
free water was used to bring the volume to 12 µl. The mixture was incubated at 70°C 
for 10 min in the PCR machine with heated lid, then placed on ice. In a second tube, 
the Reverse Transcription Master Mix was assembled by adding the following 
components at room temperature: 2 µl of 10 x First Strand Buffer, 1 µl of 
Ribonuclease Inhibitor, 4 µl of dNTP Mix and 1 µl of Reverse Transcriptase. The 8µl 
of the Reverse Transcription Master Mix was added to the RNA sample and incubated 
for 2 h at 42°C in the PCR machine with heated lid, then placed on ice. 
For the second strand cDNA synthesis, the reagents were added to the first 
strand reaction sample in the order: 63 µl of nuclease-free water, 10 µl of 10 x Second 
Strand Buffer, 4 µl of dNTP Mix, 2 µl of DNA Polymerase and 1 µl of RNase H, the 
total volume was 100 µl. The reaction mixture was incubated for 2 h at 16°C in the 
PCR machine without heated lid. 
Double stranded cDNA was cleaned by using the MessageAmpTM aRNA Kit 
(Ambion) according to the manufacturer’s protocol.  
In vitro transcription for cRNA amplification was made with MessageAmpTM 
aRNA Kit (Ambion) according to the manufacturer’s protocol. The transcription 
reaction was prepared by adding the components at room temperature in the order 
shown: 16 µl of double-stranded cDNA from above, 4 µl of 75mM T7 ATP, 4 µl of 
75mM T7 CTP, 4 µl of 75mM T7 GTP, 4 µl of 75mM T7 UTP and 4 µl of T7 
Enzyme Mix. The reaction was incubated for 7 h at 37°C water bath with gently 
mixing the contents of the tube every 30-45 min during the incubation. After 
incubation, the template cDNA was removed from the cRNA with DNase I treatment 
for 30 min at 37°C. 60 µl of Elution Solution was added to the cRNA sample to bring 
the final volume to 100 µl. 
cRNA was purified by using the MessageAmpTM aRNA Kit (Ambion) 
according to the manufacturer’s protocol.  
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2.2.12.1.3 Second round RNA amplification and synthesis of biotin labelled cRNA probe  
After first round RNA amplification, cRNA was precipitated and resuspended in 8 µl 
RNase free water in 0.5 ml microfuge tube. For the first strand cDNA synthesis, 2 µl 
Second Round Primers (MessageAmpTM aRNA Kit, Ambion) was added to the RNA 
sample and incubated for 10 min at 70°C in the PCR machine with heated lid, then the 
sample was cooled on ice for 2 min. The master mix was prepared as follows: 4 µl 5 x 
First Strand Buffer (Invitrogen), 2 µl 0.1 M DTT (Invitrogen), 1 µl Ribonuclease 
inhibitor (40 U/µl, MBI Fermentas ), 1 µl 10 mM dNTP mix and 2 µl Superscript II 
RNase H- reverse transcriptase (200 U/µl, Invitrogen) and mixed by pipetting up and 
down. The 10 µl master mix was added to the denatured RNA and primer mixture, 
making a final volume of 20 µl. The components were mixed thoroughly by gently 
pipetting up and down several times. After a brief spinning samples were collected at 
the bottom of the tube. Samples were incubated for 2 h at 37°C in the PCR machine 
with heated lid, 1 µl RNase H (2 U/µl, Invitrogen) was added to remove the RNA 
template and incubated for 20 min at 37°C. Samples were heated at 95°C for 5 min to 
inactivate the RNase H, and then chilled on ice for 2 min and spun briefly to collect 
the sample at the bottom of the tube. 
For the second strand cDNA synthesis, 2 µl T7-Oligo (dT) promoter primer 
(50 µM, Affymetrix) was added to the chilled sample from the previous step and 
incubated for 6 min at 70°C. Samples were chilled on ice for 2 min and spun briefly to 
collect the sample at the bottom of the tube. The master mix was prepared as follows: 
33.5 µl RNase free H2O, 15 µl 5 x Second Strand Buffer (Invitrogen), 1.5 µl 10 mM 
dNTP mix and 2 µl DNA Polymerase I (10 U/µl, Invitrogen) and mixed by pipetting 
up and down several times. The 52 µl master mix was added to the sample and 
incubated at 16°C for 2 h. 2 µl T4 DNA Polymerase (5 U/µl, Invitrogen) was added to 
the sample and incubated at 16°C for 10 min. 
Double strand cDNA was cleaned by Sample Cleanup Module (Affymetrix) 
according to the manufacturer’s protocol.  
In vitro transcription for cRNA amplification and labelling was made with 
BioArrayTM HighYieldTM RNA Transcript Labeling Kit (Affymetrix) according to the 
manufacturer’s protocol. The template cDNA and other reaction components were 
added to the tube at room temperature in the order shown: 12 µl of template cDNA, 
10 µl of RNase-free water, 4 µl of 10 x HY Reaction Buffer, 4 µl of 10 x Biotin-
Labeled Ribonucleotides, 4 µl of 10 x DTT, 4 µl of RNase Inhibitor Mix and 2 µl of 
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20 x T7 RNA Polymerase. The reaction was incubated for 4.5 h at 37°C water bath 
with gently mixing the contents of the tube every 30-45 min during the incubation.  
Biotin-labelled cRNA was cleaned by Sample Cleanup Module (Affymetrix) 
according to the manufacturer’s protocol. 
2.2.12.1.4 Quantification and fragmentation of cRNA probe 
The purified cRNA probe was diluted to 1:100 for the photometric quantification. The 
cRNA must be at a minimum concentration of 0.6 µg/µl. Fragment an appropriate 
amount of cRNA for hybridization cocktail and gel analysis. 5 x Fragmentation Buffer 
was supplied with the GeneChip Sample Cleanup Module. 2 µl 5 x Fragmentation 
Buffer was added for every 8 µl RNA plus water, the reaction was incubated for 35 
min in a 94°C water bath. The Fragmentation buffer has been optimized to break 
down full-length cRNA to 35 to 200 base fragments by metal-induced hydrolysis. The 
final concentration of RNA in the fragmentation mix can range from 0.5 µg/µl to 2 
µg/µl. Undiluted, fragmented sample RNA was stored at -70°C until ready to perform 
the hybridization. 
2.2.12.2 Eukaryotic Target Hybridization 
The hybridization cocktail was prepared according to the Affymetrix guidelines by 
mixing the following components for each target, volumes were scaled up for 
hybridization to multiple probe arrays. Frozen stocks of 20 x GeneChip Eukaryotic 
Hybridization Control were heated to 65°C for 5 min to completely resuspend the 
cRNA before aliquotting. 
Table 6 Components of the hybridization cocktail 
Component Standard Array Final Concentration 
Fragmented cRNA 15 µg 0.05 µg/µl 
Control Oligonucleotide B2 
(3nM) 
5 µl 50 pM 
20 x Eukaryotic Hybridization 
Controls (bioB, bioC, bioD, cre) 
15 µl 1.5, 5, 25 and  
100 pM respectively 
Herring Sperm DNA  
(10 mg/ml) 
3 µl 0.1 mg/ml 
Acetylated BSA (50 mg/ml) 3 µl 0.5 mg/ml 
2 x Hybridization Buffer 150 µl 1 x 
H2O To final volume of 300 µl  
Final volume 300 µl  
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The probe array was equilibrated to room temperature immediately before use, 
the Hybridization Cocktail was heated to 99°C for 5 min in a heat block, meanwhile, 
the array was wetted by filling it through one of the septa with 200 µl 1 x 
hybridization buffer using a micropipettor and appropriate tips and incubated at 45°C 
for 10 min with rotation. The hybridization cocktail that had been heated at 99°C was 
transferred to a 45°C heat block for 5 min and centrifuged at maximum speed in a 
microcentrifuge for 5 min to remove any insoluble material from the hybridization 
mixture. The buffer solution was removed from the probe array cartridge and 200 µl 
of the clarified hybridization cocktail was filled avoiding any insoluble matter in the 
volume at the bottom of the tube. The probe array was placed in rotisserie box in 45°C 
oven with 60 rpm rotation and hybridized for 16 h. 
2.2.12.3 Washing, Staining and Scanning 
The washing, staining and scanning procedures were performed in the Fluidics Station 
400 (Affymetrix) at the Max Planck Institute for Terrestrial Microbiology, Marburg. 
Antibody amplification for eukaryotic targets washing and staining procedure was 
used. The SAPE solution mix and antibody solution were prepared as follows: 
Table 7 SAPE solution mix 
Components Volume Final Concentration 
2 x MES Stain Buffer 600.0 µl 1 x 
50 mg/ml acetylated BSA 48.0 µl 2 mg/ml 
1 mg/ml Streptavidin Phycoerythrin (SAPE) 12.0 µl 10 µg/ml 
DI H2O 540.0 µl  
Total 1200 µl  
The mixture was mixed well and divided into two aliquots of 600 µl each to be 
used for stains 1 and 3, respectively. 
Table 8 Antibody solution mix 
Components Volume Final Concentration 
2 x MES Stain Buffer 300.0 µl 1 x 
50 mg/ml acetylated BSA 24.0 µl 2 mg/ml 
10 mg/ml Normal Goat IgG 6.0 µl 0.1 mg/ml 
0.5 mg/ml biotinylated antibody 3.6 µl 3 µg/ml 
DI H2O 266.4 µl  
Total 600 µl  
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After 16 h of hybridization, the hybridization cocktail was removed from the 
probe array, 250 µl of non-stringent wash buffer was filled in the probe array 
completely. Fluidics protocols were as follows: 
Table 9 Fluidics protocols 
 Standard Format (EukGE-WS2) 
Post Hyb Wash 1 10 cycles of 2 mixes/cycle with Wash Buffer A at 25°C 
Post Hyb Wash 2 4 cycles of 15 mixes/cycle with Wash Buffer B at 50°C 
Stain Stain the probe array for 10 min in SAPE solution at 25°C 
Post Stain Wash 10 cycles of 4 mixes/cycle with Wash Buffer A at 25°C 
2nd Stain Stain the probe array for 10 min in antibody solution at 25°C 
3rd Stain Stain the probe array for 10 min in SAPE solution at 25°C 
Final Wash 
 
15 cycles of 4 mixes/cycle with Wash Buffer A at 30°C 
The holding temperature is 25°C 
Completion of the wash protocols, the probe arrays were scanned at 570nm 
wavelength using GeneArray Scanner (Affymetrix, USA). 
2.2.12.4 Microarray analysis 
Data were analyzed and provided by Dr. B. Samans, an expert of microarray analysis 
in Dept. of Medical Biometry and Epidemiology, University Marburg. 
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3 Results 
3.1 Gene expression analysis of calcitonin receptor isoforms in 
rat brain 
3.1.1 RT-PCR analysis of CT(a) and CT(b) expression in rat brain 
To investigate the region-specific gene expression of the two calcitonin receptor 
isoforms CT(a) and CT(b) in rat brain, total RNA extracts from cortex, hippocampus, 
thalamus, hypothalamus, cerebellum, brain stem and pituitary were analyzed by RT-
PCR using isoform-specific primer pairs. As shown in Fig. 3, CT(a) mRNA was 
detected in all of the tissues examined with similar expression levels, except cortex 
which showed lower levels. In contrast, CT(b) gene expression varied between 
different brain regions. The strongest signals were detected in hypothalamus followed 
by thalamus and brain stem, hippocampus and pituitary. Very weak signals were 
observed in cerebellum. No PCR product for CT(b) could be detected in the cortex. 
 
Fig. 3 RT-PCR analysis of CT(a) and CT(b) expression in rat brain 
Gel electrophoresis of PCR products for CT(a) and CT(b) amplified from RNA extracts of dissected brain 
regions and the pituitary. A 270bp amplicon for CT(a) is detected in all tissues examined (upper panel). 
A 348bp amplicon for CT(b) is detected in hypothalamus, thalamus and brain stem, hippocampus, 
pituitary and cerebellum (middle panel). Note the lack of a specific PCR product for CT(b) in cerebral 
cortex. RT-PCR for the house-keeping gene GAPDH served as positive control (lower panel). As 
negative control reverse transcriptase is omitted from the cDNA synthesis of a hypothalamic RNA 
sample (-RT). 
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3.1.2 Cellular expression patterns of calcitonin receptor mRNAs in rat brain 
revealed by in situ hybridization 
For comparative analysis of the regional distribution of CT(a) and CT(b) isoforms in rat 
brain, ISH was performed using 35S-labeled cRNA probes. A CT(a/b) probe was 
generated which recognized both isoforms, while the CT(b) probe was designed to 
recognize only the CT(b) isoform. The isoform specificity of the probes is illustrated in 
Fig. 4. 
CT(a) 
CT(b)  
Gene structure
CT(a)
CT(b)
mRNA
MHIFHHNTYMWTMQWELSPPLPLSAHEGKMDPHDSEV  
CTa/b probe
CTb probe
exonintron
primer 
primer
primer
primer
gcatatttttcatcataacacatatatgtggacaatgcagtgggaactgtcaccacc
cttacccctgagtgcacacgagggaaagatggaccctcatgacagtgaagtgat 111bp
37aa
 
Fig. 4 Calcitonin receptor gene structure 
The two rat calcitonin receptor isoforms CT(a) and CT(b) are generated by alternative splicing. Both 
isoforms differ in the presence of a 111bp insert (exon 9) in CT(b) which corresponds to a 37 amino acid 
insert in the predicted second extracellular domain. 
Representative X-ray autoradiograms illustrate the distribution patterns of CT 
receptors in rat brain in Fig. 5. For a detailed analysis of cellular expression of CT 
receptor, hybridized slides were coated with nuclear emulsion and examined under a 
light microscope (Fig. 6 and Fig. 7). A subjective analysis of CT transcript levels in 
different brain region was performed, which is summarized in table 10. 
In the telencephalon, intense hybridization signals with the CT(a/b) probe and 
the CT(b) probe were observed in the accumbens nucleus (Fig. 5A, Fig. 6A, Fig. 7A), 
lateral septal nucleus (Fig. 5B, Fig. 6B, Fig. 7B), bed nucleus of the stria terminalis 
(Fig. 5C, Fig. 6C, Fig. 7D) and various subdivisions of the amygdala (Fig. 5F, 5G, 5H, 
5I, Fig. 6G, 6I, Fig. 7G, 7H, 7I). 
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In the diencephalon, CT receptor mRNAs were strongly expressed in many 
hypothalamic nuclei. Intense expression was detected in the septohypothalamic 
nucleus (Fig. 5C, Fig. 6C, Fig. 7C), the peri- and paraventricular nucleus (Fig. 5F, Fig. 
6F, 6G, Fig. 7F, 7G), suprachiasmatic nucleus (Fig. 5D, Fig. 6D, Fig. 7F), as well as 
in the dorsomedial (Fig. 5G, Fig. 6H, Fig. 7H) and arcuate (Fig. 5H, Fig. 6I, Fig. 7I) 
hypothalamic nuclei. Intense to moderate expression was observed in the anterior (Fig. 
5C, Fig. 6C, Fig. 7C) and lateral (Fig. 5H, Fig. 6I, Fig. 7I) hypothalamic areas. High 
expression levels were also present in the tuberal magnocellular nucleus (Fig. 5I), and 
premammillary nucleus (data not shown). Moderate signals for CT(a/b) probe (Fig. 5I, 
Fig. 6J) and low signals for CT(b) probe (Fig. 7J) were observed in the lateral 
habenular nucleus. Strong signals for CT(a/b) probe but not for CT(b) probe were 
observed in the subfornical organ (Fig. 5D, Fig. 6E, Fig.7E). 
In the mesencephalon, intense expression of CT receptor mRNAs was 
observed in the dorsal raphe nucleus (Fig. 5L, Fig. 6L, Fig. 7K). Moderate expression 
was observed in the lateral ventral periaqueductal gray, the lateral substantia nigra and 
the ventral tegmental area (Fig. 5J). CT receptors were also moderately expressed in 
the paratrochlear nucleus, median raphe nucleus, subpeduncular, pedunculopontine 
and the ventral tegmental nucleus (Fig. 5K, 5L, Fig. 6K, 6L). Weak expression of 
CT(b) isoform was found in the lateral ventral periaqueductal gray, ventral tegmental 
area, subpeduncular tegmental nucleus and the pedunculopontine tegmental nucleus 
(see table 10). 
In the brainstem, intense expression of CT receptor mRNAs was observed in 
the locus coeruleus, subcoeruleus nucleus (dorsal part), raphe magnus nucleus (Fig. 5P, 
Fig. 6P, Fig. 7N), area postrema and the nucleus of the solitary tract (Fig. 5R, Fig. 6R, 
Fig. 7O). CT receptors were moderately expressed in the dorsal and laterodorsal 
tegmental nucleus, lateral parabrachial nucleus, reticulotegmental nucleus of the pons 
(Fig. 5M, 5N, Fig. 6M, 6N, Fig. 7L, 7M), raphe obscurus nucleus, raphe pallidus 
nucleus and the lateral reticular nucleus (Fig. 5Q, 5R, Fig. 6Q, 6R, Fig. 7O). Signals 
were detectable for CT(a/b) probe in the dorsomedial tegmental area (Fig. 5O, Fig. 6O), 
parvocellular reticular nucleus, gigantocellular reticular nucleus, lateral 
paragigantocellular nucleus (Fig. 5Q, Fig. 6Q) and the ventral medullary reticular 
nucleus (Fig. 5R, Fig. 6R). In contrast, specific signals for CT(b) probe in these regions 
were undetectable. 
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Fig. 5 Mapping of calcitonin receptor mRNA expression in rat brain 
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Representative X-ray film autoradiograms of coronal 14-µm-thick sections through the rat brain in 
rostral to caudal orientation illustrating the regional distribution of CT receptors. Consecutive brain 
sections are hybridized with a 35S-labeled cRNA probe detecting both CT(a) and CT(b) mRNA. Acb, 
accumbens ncl.; AHC, anterior hypothalamic area, central; AMPO, anterior medial preoptic ncl.; AP, 
area postrema; Arc, arcuate hypothalamic ncl.; BLP, basolateral amygdaloid ncl., post; BMP, 
basomedial amygdaloid ncl., post; BST, bed nucleus of the stria terminalis; BSTIA, bed nucleus of the 
stria terminalis, intraamygdaloid div; CeM, central amygdaloid ncl., med div; DMD, dorsomedial 
hypothalamic ncl.; DMTg, dorsomedial tegmental area; DR, dorsal raphe ncl.; DTgP, dorsal tegmental 
ncl., pericentral; Gi, gigantocellular reticular ncl.; LA, lateroanterior hypothalamic ncl.; LaDL, lateral 
amygdaloid ncl., dorsolateral; LaVM, lateral amygdaloid ncl., ventromedial; LC, locus coeruleus; 
LDTg, laterodorsal tegmental ncl.; LH, lateral hypothalamic area; LHb, lateral habenular ncl.; LPB, 
lateral parabrachial ncl.; LPGi, lateral paragigantocellular ncl.; LRt, lateral reticular ncl.; LSV, lateral 
septal ncl.; LVPAG, lateral ventral periaqueductal gray; MdV, medullary reticular ncl., ventral; Me, 
medial amygdaloid ncl.; MeA, medial amygdaloid ncl., anterior; MPA, medial preoptic area; NTS, 
nucleus of the solitary tract; Pa4, paratrochlear ncl.; PaAP, paraventricular hypothalamic ncl., ant parvo; 
PCRt, parvocellular reticular ncl.; PMCo, posteromedial cortical amygdaloid ncl.; PPTg, 
pedunculopontine tegmental ncl.; PVN, paraventricular hypothalamic ncl.; RMg, raphe magnus ncl.; 
ROb, raphe obscurus ncl.; RPa, raphe pallidus ncl.; RtTg, reticulotegmental nucleus pons; SCh, 
suprachiasmatic ncl.; SFO, subfornical organ; SHy, septohypothalamic ncl.; SNL, substantia nigra, 
lateral; SPTg, subpeduncular tegmental ncl.; StHy, striohypothalamic ncl.; SubCD, subcoeruleus 
nucleus, dorsal; TMC, tuberal magnocellular ncl.; VTA, ventral tegmental area; VTg, ventral tegmental 
ncl. Exposure of X-ray film 70h. 
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Fig. 6 Cellular distribution of calcitonin receptor mRNAs in rat brain 
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Representative low power microscopic darkfield autoradiograms illustrating the expression pattern of 
CT receptors in frozen sections through the rat brain after hybridization with 35S-labeled riboprobes 
detecting both CT(a) and CT(b) transcripts. CT receptors are detected in Acb, accumbens ncl.; AHA, 
anterior hypothalamic area; AHC, anterior hypothalamic area, central; AMPO, anterior medial preoptic 
ncl.; AP, area postrema; Arc, arcuate hypothalamic ncl.; BST, bed nucleus of the stria terminalis; 
BSTIA, bed nucleus of the stria terminalis, intraamygdaloid div; CeM, central amygdaloid ncl., med 
div; DA, dorsal hypothalamic area; DMD, dorsomedial hypothalamic ncl.; DMTg, dorsomedial 
tegmental area; DR, dorsal raphe ncl.; DTgP, dorsal tegmental ncl., pericentral; fr, fasciculus 
retroflexus; Gi, gigantocellular reticular ncl.; LA, lateroanterior hypothalamic ncl.; LC, locus coeruleus; 
LDTg, laterodorsal tegmental ncl.; LH, lateral hypothalamic area; LHb, lateral habenular ncl.; LPB, 
lateral parabrachial ncl.; LPGi, lateral paragigantocellular ncl.; LRt, lateral reticular ncl.; LSV, lateral 
septal ncl.; MdV, medullary reticular ncl., ventral; Me, medial amygdaloid ncl.; MeAD, medial 
amygdaloid nucleus, anterodorsal; MeAV, medial amygdaloid nucleus, anteroventral; MePD, medial 
amygdaloid nucleus, posterodorsal; MePV, medial amygdaloid nucleus, posteroventral; MnPO, median 
preoptic ncl.; MnR, median raphe ncl.; MPA, medial preoptic area; MPO, medial preoptic ncl.; NTS, 
nucleus of the solitary tract; Pa4, paratrochlear ncl.; PaAP, paraventricular hypothalamic ncl., ant parvo; 
PCRt, parvocellular reticular ncl.; Pe, periventricular hypothalamic ncl.; PeF, perifornical ncl.; PPTg, 
pedunculopontine tegmental ncl.; PVN, paraventricular hypothalamic ncl.; RMg, raphe magnus ncl.; 
ROb, raphe obscurus ncl.; RPa, raphe pallidus ncl.; RtTg, reticulotegmental nucleus pons; SCh, 
suprachiasmatic ncl.; SFO, subfornical organ; SHy, septohypothalamic ncl.; SPTg, subpeduncular 
tegmental ncl.; StHy, striohypothalamic ncl.; SubCD, subcoeruleus nucleus, dorsal; VMH, 
ventromedial hypothalamic ncl.; VTg, ventral tegmental ncl.. 3V, third ventricle. Exposure time: 14 
days. Scale bar: 200µm. 
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Fig. 7 Expression of CT(b) mRNA in rat brain 
Representative low power microscopic darkfield autoradiograms illustrating the expression pattern of 
CT(b) in frozen sections through the rat brain after hybridization with 35S-labeled riboprobes. CT(b) 
mRNA is detected in Acb, accumbens ncl.; AHA, anterior hypothalamic area; AHC, anterior 
hypothalamic area, central; AMPO, anterior medial preoptic ncl.; AP, area postrema; Arc, arcuate 
hypothalamic ncl.; BST, bed nucleus of the stria terminalis; BSTIA, bed nucleus of the stria terminalis, 
intraamygdaloid div; CeM, central amygdaloid ncl., med div; DA, dorsal hypothalamic area; DMD, 
dorsomedial hypothalamic ncl.; DR, dorsal raphe ncl.; DTgP, dorsal tegmental ncl., pericentral; fr, 
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fasciculus retroflexus; LA, lateroanterior hypothalamic ncl.; LC, locus coeruleus; LDTg, laterodorsal 
tegmental ncl.; LH, lateral hypothalamic area; LHb, lateral habenular ncl.; LPB, lateral parabrachial ncl.; 
LRt, lateral reticular ncl.; LSV, lateral septal ncl.; Me, medial amygdaloid ncl.; MeAD, medial 
amygdaloid nucleus, anterodorsal; MeAV, medial amygdaloid nucleus, anteroventral; MePD, medial 
amygdaloid nucleus, posterodorsal; MePV, medial amygdaloid nucleus, posteroventral; MPA, medial 
preoptic area; MPO, medial preoptic ncl.; NTS, nucleus of the solitary tract; PaAP, paraventricular 
hypothalamic ncl., ant parvo; Pe, periventricular hypothalamic ncl.; PeF, perifornical ncl.; PPTg, 
pedunculopontine tegmental ncl.; PVN, paraventricular hypothalamic ncl.; RMg, raphe magnus ncl.; 
ROb, raphe obscurus ncl.; RtTg, reticulotegmental nucleus pons; SCh, suprachiasmatic ncl.; SFO, 
subfornical organ; SHy, septohypothalamic ncl.; SPTg, subpeduncular tegmental ncl.; StHy, 
striohypothalamic ncl.; SubCD, subcoeruleus nucleus, dorsal; VMH, ventromedial hypothalamic ncl.. 
3V, third ventricle. exposure time: 41 days. Scale bar: 200µm. 
Table 10 Subjective evaluation of the regional hybridization signals obtained with the CT(a/b) and 
CT(b) probes in rat brain1
 Signals with CT(a/b) probe Signals with CT(b) probe 
Telencephalon   
   Accumbens nucleus (Acb) +++++ +++ 
   Lateral septal nucleus (LSV) ++++ ++ 
   Bed nucleus of the stria terminalis (BST) ++++ + 
   Bed nu st, intraamyg div (BSTIA) ++++ ++ 
   Medial amygdaloid nu, anterior (MeA) ++++ ++ 
   Medial amyg nu, anteroventral (MeAV) ++++ ++ 
   Medial amyg nu, anterodorsal (MeAD) ++++ ++ 
   Central amyg nu, med div (CeM) ++++ ++ 
   Cent amyg nu, med, anterod (CeMAD) ++++ ++ 
   Cent amyg nu, med, posterov (CeMPV) ++++ ++ 
   Medial amygdaloid nu (Me) ++++ ++ 
   Medial amyg nu, posterodorsal (MePD) ++++ ++ 
   Medial amyg nu, posteroventral (MePV) ++++ ++ 
   Posteromed cortical amyg nu (PMCo) ++++ ++ 
   Basomedial amygdaloid nu, post (BMP) ++++ ++ 
   Basolateral amygdaloid nu, post (BLP) ++++ ++ 
   Lateral amyg nu, ventromedial (LaVM) ++++ ++ 
   Lateral amygdaloid nu, dorsolat (LaDL) ++++ ++ 
Diencephalon   
   Median preoptic nucleus (MnPO) +++++ + 
   Medial preoptic area (MPA) +++++ ++ 
   Anterior medial preoptic nu (AMPO) +++++ +++ 
   Septohypothalamic nu (SHy) +++++ +++ 
   Striohypothalamic nu (StHy) +++++ ++ 
   Medial preoptic nu (MPO) +++++ +++ 
   Subfornical organ (SFO) +++++ - 
   Periventricular hypoth nu (Pe) +++++ +++ 
   Paravent hypoth nu, ant parvo (PaAP) +++++ +++ 
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 Signals with CT(a/b) probe Signals with CT(b) probe 
   Anterior hypoth area (AHA) +++* +* 
   Lateroanterior hypoth nu (LA) +++* +* 
   Suprachiasmatic nu (SCh) +++++ +++ 
   Paravent hy nu, med parvocell (PaMP) +++++ +++ 
   Paravenr hy nu, lat magnocell (PaLM) +++++ +++ 
   Paraventricular hypoth nu, vent (PaV) +++++ +++ 
   Anterior hypoth area, central (AHC) +++* +* 
   Dorsal hypoth area (DA) ++++ ++ 
   Dorsomedial hypothalamic nu (DMD) +++++ +++ 
   Ventromedial hypoth nu (VMH) +++++ +++ 
   Lateral hypoth area (LH) +++* +* 
   Perifornical nu (PeF) ++++* +* 
   Arcuate hypoth nu (Arc) +++++ +++ 
   Tuberal magnocellular nu (TMC) +++++ +++ 
   Premammillary nu, ventral (PMV) ++++ ++ 
   Premammillary nu, dorsal (PMD) ++++ ++ 
   Lateral habenular nu (LHb) +++* * 
   Fasciculus retroflexus (fr) +* - 
Mesencephalon   
   Lateral ventral periaqueductal gray (LVPAG) ++* * 
   Substantia nigra, lateral (SNL) ++* - 
   Ventral tegmental area (VTA) ++* * 
   Dorsal raphe nu (DR)    +++ + 
   Paratrochlear nu (Pa4) ++* - 
   Median raphe nu (MnR) ++* - 
   Subpeduncular tegmental nu (SPTg) ++* * 
   Pedunculopontine tegmental nu (PPTg) ++* * 
   Ventral tegmental nu (VTg) ++* - 
Brainstem   
   Dorsal tegmental nu, pericentral (DTgP) ++++ ++ 
   Laterodorsal tegmental nu (LDTg) +++* +* 
   Lateral parabrachial nu (LPB) +++* +* 
   Subcoeruleus nu, dorsal (SubCD) +++* +* 
   Reticulotegmental nu pons (RtTg) +++* * 
   Dorsomedial tegmental area (DMTg) ++* - 
   Locus coeruleus (LC) +++++ +++ 
   Raphe magnus nu (RMg) +++++ ++ 
   Parvocellular reticular nu (PCRt) +++* - 
   Gigantocellular reticular nu (Gi) +++* - 
   Lateral paragigantocellular nu (LPGi) +++* - 
   Raphe obscurus nu (ROb) ++* * 
   Raphe pallidus nu (RPa) ++* * 
   Area postrema (AP) ++++ + 
   Nu solitary tract (NTS) ++++ + 
   Medullary reticular nu, ventral (MdV) +++* - 
   Lateral reticular nu (LRt) +++* * 
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For each individual probe the hybridization signal density was evaluated subjectively and ranked as 
follows: +++++, maximum density; ++++, very dense; +++, dense; ++, moderate; +, low; -, below 
detection; *, single scattered neurons. 
3.2 RT-PCR analysis of CT(a) and CT(b) transcripts in the RNA 
extracts of microdissected area postrema (AP) and nucleus 
of the solitary tract (NTS) 
In situ hybridization analysis revealed the expression of CT receptors in the area 
postrema (AP) and the nucleus of the solitary tract (NTS) of the brain stem. To 
investigate which isoform was expressed in these regions, LCM combined with RT-
PCR analysis was performed using isoform-specific primer pairs. The area postrema 
(AP) and the nucleus of the solitary tract (NTS) were identified in cresyl violet stained 
sections (Fig. 8A, D) and laser-microdissected regions (Fig. 8C, F) (see 2.2.4.2 for 
details). RNA extracts from microdissected nuclei of 5 sections were pooled and 
subjected to one-round RNA amplification followed by RT-PCR. As shown in Fig. 8G, 
both calcitonin receptor isoforms of CT(a) and CT(b) were expressed in AP and NTS. 
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Fig. 8 RT-PCR analysis of CT(a) and CT(b) mRNA expression in  
microdissected area postrema and the nucleus of the solitary tract 
Expression of CT(a) and CT(b) isoforms in the area postrema (AP) and the nucleus of the solitary tract 
(NTS) is examined by laser capture microdissection (LCM) (A-F) in combination with RT-PCR 
analysis (G). First, the AP is microdissected from cresyl violet acetate-stained tissue sections (A-C). 
LCM of the NTS (D-F) is performed after removal of the dorsal motor ncl.of vagus (X). (A, D) before 
microdissection, (B, E) after microdissection, (C, F) microdissected material, (G) RT-PCR analysis of 
amplified RNA extracts from AP and NTS microdissected from 10 sections. A 270bp fragment 
representing CT(a) mRNA and a 348bp fragment representing CT(b) mRNA are detected in both regions 
(G). Omission of reverse transcriptase (-RT) as negative control. 
3.3 Expression of calcitonin receptor isoforms in phenotype-
identified neurons in hypothalamus 
3.3.1 Arcuate nucleus (Arc) 
The expression of CT receptor isoforms in neuronal subpopulations of the arcuate ncl. 
characterized by their expression of the neuropeptides neuropeptide Y (NPY), pro-
opiomelanocortin (POMC) or cocaine- and amphetamine-regulated transcript (CART) 
was investigated by dual in situ hybridization using digoxigenin-labeled probes for the 
neuropeptide mRNAs and radiolabeled probes for the CT receptor mRNAs. All NPY 
neurons exhibited positive hybridization signals with both the CT(a/b) probe (Fig. 9A) 
and the CT(b) probe (Fig. 9B). Since the signals with the shorter CT(b) probe in NPY 
neurons were as strong as the signals with the CT(a/b) probe it was concluded that NPY 
neurons predominantly express the CT(b) isoform. As summarized in table 11, 54% of 
POMC neurons and 48% of CART neurons were found to hybridize with the CT(a/b) 
probe (Fig. 9C, double arrows, 9E, double arrows). No hybridization signals for CT(b) 
mRNA could be detected in POMC neurons or CART neurons (Fig. 9D, 9F) 
suggesting that a subpopulation of POMC neurons and CART neurons express 
selectively the CT(a) isoform. 
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Fig. 9 Colocalization of CT receptor isoforms with NPY, POMC or CART in 
neurons of the arcuate nucleus 
Brightfield microscopic images showing the coexpression pattern of CT receptor mRNAs with NPY (A, 
B), POMC (C, D) and CART (E, F), respectively, in representative sections through the arcuate nucleus 
of the male Wistar rats. NPY, POMC and CART transcripts are detected with digoxigenin (DIG)-
labeled probes producing a dark violet reaction precipitate and CT mRNAs with 35S-labeled probes 
represented by white grains. The Radiolabeled CT(a/b) riboprobe can detect both isoforms, while the 
radiolabeled CT(b) riboprobe is specific for the CT(b) isoform. Note both CT(a/b) and CT(b) probes label 
all NPY neurons (A, B, double arrows), while CT(a/b) signals are restricted to a subpopulation of POMC 
and CART neurons (C, E, double arrows). Most POMC and CART neurons do not express detectable 
levels of CT(b) mRNA (D, F) suggesting selective expression of the CT(a) isoform in POMC and CART 
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neurons. 3V, third ventricle. Exposure times: 16 days for probe CT(a/b), 24 days for probe CT(b). Scale 
bar in F: 50µm. 
3.3.2 Paraventricular nucleus (PVN) 
The expression of CT receptor isoforms in corticotropin-releasing hormone (CRH) 
and thyrotropin-releasing hormone (TRH) neurons in the PVN was investigated using 
dual in situ hybridization. As shown in Fig. 10 and table 11, 44% of CRH neurons (A, 
double arrows) and 23% of TRH neurons (C, double arrows) were found to express 
CT receptors. CT(b) specific transcripts were detected in about 24% of CRH neurons 
(B, double arrows) and 22% of TRH neurons (D, double arrows). 
 
Fig. 10 Colocalization of CT receptor isoforms with CRH and TRH in neurons of 
the paraventricular nucleus 
Representative brightfield images showing the coexpression pattern of CT receptor mRNAs with CRH 
(A, B) and TRH (C, D), respectively. CRH and TRH transcripts are detected with digoxigenin (DIG)-
labeled probes producing a dark violet reaction precipitate and CT mRNAs with 35S-labeled probes 
represented by white grains. Note that a subpopulation of CRH (A, double arrows) and TRH (C, double 
arrows) neurons exhibit a positive hybridization signal with the CT(a/b) probe, CT(b) specific signals are 
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found in a subpopulation of CRH (B, double arrows) and TRH (D, double arrows) neurons. Exposure 
times: 16 days for probe CT(a/b), 24 days for probe CT(b). Scale bar in F: 25µm. 
3.3.3 Lateral hypothalamic area (LHA) 
The expression of CT receptor isoforms in orexin, melanin-concentrating hormone 
(MCH) and cocaine- and amphetamine-regulated transcript (CART) neurons in the 
LHA was investigated using dual in situ hybridization. As shown in Fig. 11, all orexin 
neurons were found to hybridize with the CT(a/b) probe (Fig. 11A, double arrows). 
Strong signals for CT(a/b) were also present in another subpopulation of neurons which 
did not express orexin (Fig. 11A, arrows). The CT(b) probe labeled virtually all orexin 
neurons (Fig. 11B, double arrows). The signals for CT(a/b) in orexin neurons were 
weaker than those for CT(b) suggesting that orexin neurons predominantly express the 
CT(b) isoform. Strong signals for CT(b) in other than orexin neurons were not observed. 
Hybridization signals for CT receptor mRNAs could neither be detected in MCH 
neurons (Fig. 11C, 11D) nor in CART neurons (Fig. 11E, 11F) located in the lateral 
hypothalamic area, suggesting the lack of CT receptors in these cell types. The results 
are summarized in table 11. 
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Fig. 11 Colocalization of CT receptor isoforms with orexin, MCH and CART in 
the lateral hypothalamic area 
Representative brightfield microscopic images showing the coexpression pattern of CT receptor 
mRNAs with orexin (A, B), MCH (C, D) and CART (E, F), respectively. Orexin, MCH and CART 
transcripts are detected with digoxigenin (DIG)-labeled probes producing a dark violet reaction 
precipitate and CT mRNAs with 35S-labeled probes represented by white grains. Note that nearly all 
orexin neurons (A, B, double arrows) exhibit positive hybridization signals with CT(a/b) probe and CT(b) 
probe, while most MCH and CART neurons (C-F, arrowheads) do not express detectable levels of CT 
receptor mRNAs suggesting the lack of CT receptors in these cell types. Exposure times: 16 days for 
probe CT(a/b), 24 days for probe CT(b). Scale bar in F: 50µm. 
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Table 11 Cell specific expression of CT(a) and CT(b) in peptidergic neurons relating food intake 
regulation in hypothalamus 
CT receptor isoforms Hypothalamic 
nucleus / area 
Peptidergic 
phenotype CT(a/b) probe CT(b) probe CT(a) CT(b)
Arc NPY 100% 100% ? Yes 
 POMC 54%* 0% Yes No 
 CART 48%* 0% Yes No 
PVN CRH 44%* 24%* ? Yes 
 TRH 23%* 22%* ? Yes 
LHA orexin 100% 100% ? Yes 
 MCH 0% 0% No No 
 CART 0% 0% No No 
 Unidentified neurons 100% 0% Yes No 
*Note: To determine the coexpression of CT receptors with POMC and CART, 305 POMC neurons in 
9 sections and 178 CART neurons in 7 sections from 3 control rats were counted, respectively. To 
determine the coexpression of CT receptors with CRH and TRH, 594 CRH neurons and 504 TRH 
neurons in 10 sections from 3 control rats were counted, respectively. To determine the coexpression of 
CT(b) with CRH and TRH, 442 CRH neurons and 211 TRH neurons in 7 sections from 3 control rats 
were counted, respectively. 
3.4 Expression of calcitonin receptor isoforms in phenotype-
identified neurons in brain stem 
In order to clarify the cellular distribution of CT receptor isoforms in the area 
postrema, dual in situ hybridization analysis with CT receptor and TRH probes was 
performed. As shown in Fig. 12, no hybridization signals for CT(a/b) were observed in 
THR neurons in the area postrema. 
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Fig. 12 Lack of calcitonin (CT) receptor expression in thyrotropin-releasing 
hormone (TRH) neurons of the area postrema 
Representative brightfield microscopic image demonstrating that TRH neurons do not express CT 
receptor mRNA in the area postrema. Immunodetection of the digoxigenin-labeled TRH probe 
produces a dark violet reaction precipitate (arrowheads), 35S-labeling for CT(a/b) signals is represented 
by white grains (arrows). Note lack of double-labeled cells. Exposure time: 16 days for probe CT(a/b). 
Scale bar: 50µm. 
3.5 Identification of CT receptor isoforms in orexin neurons 
3.5.1 ISH with isoform-specific oligonucleotides 
To identify the CT receptor isoforms in orexin neurons, specific oligonucleotide 
probes for the CT(a) mRNA and for orexin mRNA were used to perform dual in situ 
hybridization. As shown in Fig. 13A, CT(a) was expressed in the dorsomedial 
hypothalamic nucleus (DMH), ventromedial hypothalamic nucleus (VMH), arcuate 
nucleus (ARC) and the lateral hypothalamic area (LHA). As shown in Fig. 13B, CT(a) 
was not expressed in orexin neurons. 
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Fig. 13 Expression analysis of CT(a) in orexin neurons 
(A) Darkfield image illustrating the expression of CT(a) mRNA in dorsomedial hypothalamic (DMH) 
nuclei, arcuate nucleus (ARC) and lateral hypothalamic area (LHA) using a 35S-labeled oligonucleotide 
(white grains). (B) The CT(a) probe yields a specific hybridization signal (arrow) in a cell different from 
an orexin neuron, which is labeled by the dark violet reaction precipitate of the digoxigenin-labeled 
orexin oligo probe (arrowhead). Exposure time: 43 days for 35S-labeled oligonucleotide CT(a) probe. 
Scale bar in A 100µm and in B 25µm. 
3.5.2 Identification of CT receptor isoforms in microdissected orexin-
immunoreactive neurons by RT-PCR  
To identify the selective expression of CT receptor isoforms in orexin neurons, the 
method of laser capture microdissection in combination with RT-PCR was employed. 
Immunofluorescence-labeled orexin neurons were captured and subjected to RNA 
isolation and RT-PCR. As shown in Fig. 14 D, after 50 cycles of amplification only 
CT(b) was detected in orexin neurons while both CT(a) and CT(b) were detected in 
hypothalamus. 
 
Fig. 14 Detection of CT(b) mRNA in microdissected orexin neurons 
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Immunofluorescent-labeled orexin neurons in a 10 µm thick section through rat hypothalamus, (A) 
before laser capture microdissection (LCM), (B) after LCM, (C) microdissected immunofluorescence-
labeled orexin neurons, (D) Gel electrophoresis of PCR products for CT(a) and CT(b) amplified from 
RNA extracts of 32 microdissected orexin neurons and hypothalamus. In total hypothalamic extracts 
both the 270bp amplicon for CT(a) and 348bp amplicon for CT(b) are detected. In microdissected orexin 
neurons only the 348bp amplicon for CT(b) is detected. As negative control reverse transcriptase was 
omitted from the cDNA synthesis (-RT). M: DNA size marker. 
3.6 Receptor-activity-modifying proteins (RAMPs) expression 
in orexin neurons 
To investigate which of the RAMPs, that can form receptor complexes with CT 
receptors, are expressed in orexin neurons in situ hybridization analysis was 
performed. X-ray film analysis revealed strong hybridization signals for RAMP1 in 
the caudate putamen (CPu) (Fig. 15A), for RAMP2 in the hypothalamus (HT) (Fig. 
15C), and for RAMP3 in the thalamus (Th) (Fig. 15E). The expression of RAMP 
isoforms in orexin neurons was investigated by dual in situ hybridization. Almost all 
orexin neurons were found to express RAMP2 mRNA (Fig. 15D) and RAMP3 mRNA 
(Fig. 15F). In contrast, Orexin neurons exhibited very low signals for RAMP1 (Fig. 
15B). 
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Fig. 15 Expession of RAMPs in orexin neurons 
X-ray film autoradiograms of rat brain sections after ISH illustrating the region-specific distribution of 
RAMPs (A, C, E). Representative high resolution microscopic brightfield images of dual in situ 
hybridization showing the colocalization of RAMP2 mRNA (arrows in D) and RAMP3 (arrows in F) 
represented by white grains with orexin (violet precipitate). Very low signals for RAMP1 could be 
detected in orexin neurons (arrows in B). CPu, caudate putamen; HT, hypothalamus; Th, thalamus. 
Scale bar in F: 25µm. 
3.7 Analysis of CGRP innervation on orexin neurons by 
immunohistochemistry 
Since calcitonin and amylin, two potential ligands for CT receptor/RAMP complexes, 
are not expressed in brain, CGRP should be considered as the likely endogenous 
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ligand. Thus, the innervation of orexin neurons by CGRP fibers was examined using 
double-immunofluorescence staining of CGRP and orexin. Using confocal 
microscopy few CGRP fibers (Fig. 16 A, C green) could be detected on orexin cell 
bodies (Fig. 16 B, C red), suggesting the possibility that CGRP may act as 
endogneous ligand on orexin neurons. 
 
Fig. 16 Double-immunofluorescence staining of CGRP and orexin 
Confocal double-immunofluorescence microscopy demonstrating a CGRP terminal (green in A and C) 
in close apposition to the cell body of an orexin neuron (red in B and C) in the lateral hypothalamic area. 
Double immunohistochemistry of orexin and CGRP with Nickel-enhanced DAB 
staining was performed to examine the spatial relationship of CGRP innervation and 
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the orexin system in the lateral hypothalamus and the posterior paraventricular 
thalamic nucleus (PVP). In the lateral hypothalamus, CGRP positive terminals were 
detected contacting the cell bodies of orexin neurons (Fig. 17A). Furthermore, CGRP 
fibers with close spatial relationship to orexin fibers were observed in the posterior 
paraventricular thalamic nucleus (PVP) (Fig. 17B). 
 
Fig. 17 Double immunohistochemistry of CGRP and orexin 
High resolution brightfield images showing a dark blue CGRP fiber (arrow in A) contacting a brown 
orexin cell body (arrowhead in A) in the lateral hypothalamic area. In the posterior paraventricular 
thalamic nucleus (PVP), the dark blue CGRP fibers exhibit close spatial relationship with brown orexin 
fibers (stars in B). Scale bar in A: 20µm. 
3.8 Characterization of the classical transmitter phenotype of 
orexin neurons 
When the work of this thesis was started the classical transmitter used by orexin 
neurons had not yet been identified. Electrophysiological studies suggested that the 
activity of orexin neurons is autostimulated involving glutamate (Li et al. 2002). In 
order to clarify the classical transmitter phenotype of orexin neurons, double labeling 
in situ hybridization analysis was performed using VGLUT2 as a marker for the 
hypothalamic glutamatergic neurons and GABA synthetic enzyme glutamate 
decarboxylase (GAD) as the marker for GABAergic neurons. VGLUT2 and GAD67 
mRNAs were found to be widely expressed through lateral hypothalamic area in 
agreement with previous studies (Rosin et al. 2003). Dual hybridization of frozen 
sections through the hypothalamus obtained from 3 animals revealed the expression of 
VGLUT2 mRNA in all orexin neurons (Fig. 18A, double arrows) strongly suggesting 
a glutamatergic phenotype of orexin neurons. Some VGLUT2 hybridization signals 
were also found in other neurons (Fig. 18A, single arrows). GAD67 mRNA was 
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detected in all of the MCH neurons indicating a GABAergic phenotype of MCH 
neurons (Fig. 18B, double arrows). Orexin neurons did not express GAD67 (data not 
shown). However, some GAD67 hybridization signals were also found in MCH-
negative neurons (Fig. 18B, single arrows) 
 
Fig. 18 Coexpression of VGLUT2 and orexin mRNA and GAD67 and MCH 
mRNA in hypothalamic neurons 
Representative combined brightfield and darkfield images illustrating colocalization of VGLUT2 and 
orexin mRNA (A, double arrows) and colocalization of GAD67 and MCH mRNA (B, double arrows) 
in hypothalamic neurons (B, double arrows). Note strong VGLUT2 signals are present in a 
subpopulation of neurons which do not express orexin mRNA (A, single arrow) and strong GAD67 
signals in a subpopulation of neurons which do not express MCH mRNA (B, single arrow). Orexin and 
MCH mRNA is detected with digoxigenin-labeled probes producing a dark violet precipitate, 
radioactive detection of VGLUT2 and GAD67 mRNA produces white grains under darkfield 
illumination. Scale bar: 25µm. 
3.9 Cellular gene expression profiling of orexin neurons 
using LCM and microarray analysis to identify fasting-
regulated genes 
In order to investigate changes of the cellular transcriptome of orexin neurons after 
fasting and to identify novel fasting-regulated genes expressed in orexin neurons, a 
fasting model was used previously reported by some groups to stimulate orexin 
neurons (Sakurai et al. 1998).To determine the differential gene expression in fasting 
versus non-fasting rats, microdissected orexin neurons were subjected to microarray 
analysis. Immunofluorescent-labeled orexin neurons were captured from 3 rats fasted 
for 48h and from 3 control rats. The captured neurons were subjected to RNA 
isolation and RNA amplification. Two rounds of RNA amplification were necessary 
to obtain enough RNA from one animal for hybridizing one chip. After labeling with 
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biotin the cRNA probes were hybridized to the GeneChip® Rat Expression 230A 
Array (2.2.12) using the Affymetrix Fluidics Station in Max Planck Institute for 
Terrestrial Microbiology, Marburg. After target hybridization, the probe arrays were 
scanned. The data were analyzed and provided by Dr. B. Samans, an expert of 
microarray analysis in Dept. of Medical Biometry and Epidemiology, University 
Marburg. 
Among about 5399 genes and 10467 ESTs represented on the Affymetrix RAE 
230A microarray, the mRNAs of the orexin neuropeptide, calcitonin receptor, 
receptor-activity-modifying proteins and the vesicular glutamate transporter were 
detected in the RNA extracts of orexin neurons. The expression levels of these genes 
were unaffected after 48h fasting. The expression of these genes in orexin neurons of 
normal animals was also demonstrated by ISH in this thesis. 
The microarray analysis of microdissected orexin neurons from rats subjected 
to fasting revealed 281 genes upregulated (1,32 to 2,61 fold) and 200 genes 
downregulated (1,32 to 2,66 fold), respectively. Enzymes, channels, receptors, 
neuropeptides and structural molecules were identified by comparing the microarray 
data with Genebank and Affymetrix gene data base. 
A list of arbitrarily selected genes (table 12) that displayed upregulation (1,46 
to 1,90 fold) and a list of arbitrarily selected genes (table 14) that displayed 
downregulation (1,45 to 1,95 fold) after fasting and that were known to be involved in 
the energy metabolism, signal transduction and neurotransmission have been compiled. 
A list of ESTs that displayed upregulation (2,61 to 1,40 fold) and a list of ESTs that 
displayed downregulation (2,27 to 1,40 fold) after fasting are shown in table 13 and 
table 15, respectively. 
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Table 12 Genes upregulated after 48h fasting in rat orexin neurons 
Gene categories and gene titles Affymetrix Nr. Genebank Accession Nr. 
Fold 
Change1
Biological process description2
Enzymes     
   ATPase, Ca++ transporting, 
plasma membrane 1 1370050_at 
NM_053311 1,80 cation transport, calcium ion transport, metabolism 
   aflatoxin B1 aldehyde reductase 1368121_at NM_013215 1,46 aflatoxin metabolism 
     
Ion channel     
   chloride channel 2 1372807_at BF402462 1,46 ion transport, chloride transport 
     
Signal transduction     
   Metallothionein 1371237_a_at AF411318 1,78 
metal ion homeostasis, zinc ion 
homeostasis, nitric oxide 
mediated signal transduction 
     
cell adhesion molecule     
   cadherin 22 1368887_at NM_019161 1,84 
cell adhesion, homophilic cell 
adhesion, brain development, 
calcium-dependent cell-cell 
adhesion 
     
Neuropeptides     
   arginine-glutamic acid dipeptide 
(RE) repeats 1371890_at 
AI172033 1,90 protein-protein interaction 
   neuropeptide FF-amide peptide 
precursor 1368383_at 
NM_022586 1,49 neuropeptide signaling pathway 
     
Structural molecules     
   vimentin 1367574_at NM_031140 1,60 
structural molecule activity, 
structural constituent of 
cytoskeleton, protein binding 
   preimplantation protein 3 1387089_at NM_133528 1,57 protein binding 
     
Receptors     
   insulin-like growth factor 1 
receptor 1368123_at 
NM_052807 1,55 insulin-like growth factor receptor signaling pathway 
   thyrotropin releasing hormone 
receptor 1369751_at 
M90308 1,50 thyrotropin-releasing hormone receptor activity 
   gamma-aminobutyric acid 
(GABA) B receptor, 1 1375720_at 
AI171785 1,47 GABA-B receptor activity 
     
Neurotransmission     
   huntingtin-associated protein 1 1369358_a_at AI412750 1,57 synaptic transmission, neurogenesis 
1 Fold change was determined by comparing the average gene expression levels of 3 fasted animals 
with that of 3 control animals. 
2 cited from affymetrix analysis data bank (https://www.affymetrix.com/analysis) 
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Table 13 ESTs upregulated after 48h fasting in rat orexin neurons 
Affymetrix Nr. Accession Nr. Fold change* 
1383141_a_at AI236700 2,61 
1372390_at AI710604 2,15 
1399063_at BE105565 1,86 
1375144_at BM388843 1,83 
1390284_at BM383683 1,83 
1371326_at BI276957 1,79 
1377506_at BI289525 1,74 
1374300_at AA997139 1,70 
1377522_a_at BI294610 1,69 
1373580_at BI289991 1,69 
1388519_at BI281906 1,68 
1377237_at AI137274 1,67 
1376240_at BG378240 1,67 
1373954_at BG381520 1,67 
1375912_a_at BI285430 1,65 
1372361_at AW529931 1,61 
1389137_at AA957183 1,59 
1371363_at BI277042 1,58 
1372875_at AI408520 1,57 
1376250_at BI284814 1,56 
1376922_at AW523772 1,55 
1375878_at BE102596 1,54 
1372727_at BM384088 1,52 
1371871_at AI409731 1,50 
1372265_at AI172218 1,50 
1374459_at AI178448 1,49 
1372304_at BG378042 1,47 
1373842_at BM390718 1,40 
* Fold change was determined by comparing the average gene expression levels of 3 fasted animals 
with that of 3 control animals. 
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Table 14 Genes downregulated after 48h fasting in rat orexin neurons 
Gene categories and gene titles Affymetrix Nr. Genebank 
Accession Nr. 
Fold 
Change1
Biological process description2
Enzymes     
   ATP synthase, H+ transporting, 
mitochondrial F1 complex, epsilon 
subunit 
1370284_at AF010323 1,48 ATP biosynthesis, ATP synthesis coupled proton transport 
     
Structural molecules     
   collagen, type III, alpha 1 1370959_at BI275716 1,95 skeletal development, phosphate transport, cell adhesion 
   nexilin 1370697_a_at AF056034 1,60 actin filament binding 
   glial fibrillary acidic protein 1368353_at NM_017009 1,56 intermediate filament-based process 
     
Ion channel     
   transient receptor potential cation 
channel, subfamily C, member 2 1389671_at 
AW252088 1,45 
cation transport, calcium ion 
transport, positive regulation of 
cytosolic calcium ion 
concentration 
     
Signal transduction     
   ras-like protein 1386967_at NM_053522 1,72 
small GTPase mediated signal 
transduction, regulation of cell 
shape, actin cytoskeleton 
organization and biogenesis 
   transforming growth factor beta 
1 induced transcript 1 1370887_at 
BI279862 1,46 response to heat 
1 Fold change was determined by comparing the average gene expression levels of 3 fasted animals 
with that of 3 control animals. 
2 cited from affymetrix analysis data bank (https://www.affymetrix.com/analysis) 
Table 15 ESTs downregulated after 48h fasting in rat orexin neurons 
Affymetrix Nr. Accession Nr. Fold change* 
1372013_at BG380285 2,27 
1367547_at BM388010 1,68 
1372789_at BF397881 1,59 
1389560_at BF284702 1,57 
1372949_at BG663067 1,56 
1372542_at BE113281 1,51 
1388626_at AI638949 1,50 
1388611_at AW252817 1,49 
1388814_at AI408110 1,47 
1371710_at BM391283 1,46 
1374298_at BG373455 1,45 
1373754_at AI599232 1,45 
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1393436_at AI549033 1,44 
1373748_at AW532566 1,44 
1376634_a_at BE109067 1,41 
1388844_at AI102904 1,41 
1375026_at AI105369 1,40 
* Fold change was determined by comparing the average gene expression levels of 3 fasted animals 
with that of 3 control animals. 
3.10 Validation of TRH receptor expression in orexin 
neurons by semi-quantitative ISH 
3.10.1 Characterization of TRH receptor subtypes in orexin neurons 
Since TRH receptors had not been described in orexin neurons previously and since 
TRH was a well known anorexigenic neuropeptide, the rat TRH receptor 1 gene, 
upregulated 1.5 fold in the microarray after fasting, was chosen as a candidate fasting-
regulated gene for further investigation. First, dual in situ hybridization was 
performed to demonstrate the expression of TRH receptor 1 or TRH receptor 2 in rat 
orexin neurons. As shown in Fig. 19, all orexin neurons were found to express 
TRHR1 mRNA (Fig. 19A, double arrows). However, no hybridization signals for 
TRHR2 could be detected in orexin neurons (Fig. 19B). These results were in 
agreement with the microarray data that revealed the expression of TRHR1 in orexin 
neurons. Moreover, no co-hybridization signals for TRHR1 and TRHR2 with MCH 
mRNA were observed (Fig. 19C, D) indicating that MCH neurons lack TRH receptor 
expression. 
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Fig. 19 Expression of TRHR1 in orexin neurons 
Representative combined brightfield and darkfield images illustrating the expression of TRH-R1 in 
orexin neurons of control animals. All of the orexin neurons are co-labeled by the TRH-R1 and the 
orexin probe (A, double arrows). Orexin neurons (B, arrowheads) are negative for TRH-R2 signals (B, 
single arrow). MCH neurons (arrowheads in C, D) are negative for TRH-R1 signals as well as for TRH-
R2 signals. Note that some MCH-negative neurons express TRHR1 or TRHR2 (single arrows in C, D). 
Orexin and MCH mRNA are detected with digoxigenin-labeled probes producing a dark violet 
precipitate. Radioactive detection of TRH-R1 and TRH-R2 mRNA produces white grains under 
darkfield illumination. Scale bar in D: 25µm. 
3.10.2 Semi-quantitative ISH analysis of fasting-induced changes of TRHR1 
mRNA in orexin neurons 
In the microarray analysis the expression of TRHR1 mRNA in orexin neurons was 
upregulated about 1.5 fold after 48h of fasting. To confirm this result semi-
quantitative image analysis of emulsion-coated autoradiograms was performed using 
the grain counting method (2.2.11). After an exposure time of 16 days, 27 sections 
from each group were subjected to grain counting. As shown in Fig. 20, the size of 
most orexin neurons ranged from 150µm2 to 500µm2. There were no significant 
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changes of the scan area per orexin neuron between the two groups (p values = 0.4) 
(Fig. 21A). The estimated grain counts representing TRHR1 mRNA levels per orexin 
neuron were increased after fasting. Of the control group 468 orexin neurons were 
examined for their TRHR1 expression levels. The average orexin neuron of the 
control group was labeled with 106 ± 2 grains. In the 48h fasted group grain counts 
increased to 123 ± 3 grains per orexin neuron (n= 322) (p values < 0.0001) (Fig. 21B). 
Comparing the grain density between the two groups, grain counts increased from 34 
± 1 grains per 100µm2 scan area in the control group to 42 ± 1 grains per 100µm2 scan 
area in the fasting group (p values < 0.0001) (Fig. 21C).  
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Fig. 20 Diagram of grain counts for the TRHR1 mRNA levels in orexin neurons 
represented by scan area 
The levels of TRHR1 mRNA are represented by estimated grain counts. The orexin neurons are shown 
as scan area. The size of orexin neurons ranged from 150 µm2 to 500 µm2. Grain counts per orexin 
neuron are increased after fasting. Blue circles represent the cells of control animals, red circles 
represent the cells of fasting animals. 
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Fig. 21 Grain-counting analysis of cellular TRHR1 mRNA levels in orexin 
neurons 
Box plot diagrams illustrating the changes of TRHR1 mRNA expression in orexin neurons after 48h 
fasting. Grain counting is performed on orexin neurons in 27 sections of each group. There is no 
significant difference of the scan area between the two groups (p values = 0.4) (A). The average number 
of silver grains per orexin neuron is increased 1.16 fold from 106 ± 2 grains (control group) to 123 ± 3 
75 
Results 
 
grains (fasting group) (p values < 0.0001) (B). The grain density is increased 1.24 fold from 34 ± 1 
grains per 100µm2 scan area in the control group to 42 ± 1 grains per 100µm2 scan area in the fasting 
group (p values < 0.0001) (C). 
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4 Discussion 
In the present study the distribution of calcitonin receptor isoforms throughout the rat 
brain has been investigated and their relationship to neuropeptidergic circuits in the 
hypothalamus and brainstem that regulate food intake and energy balance and other 
autonomic functions has been characterized. Furthermore, a pilot attempt was 
undertaken using microarray analysis to discover novel candidate genes for the 
regulation of food intake in orexin neurons. 
The main new findings of this thesis are the following: 
1) The two calcitonin receptor isoforms CT(a) and CT(b) were shown to exhibit 
distinct regional and cellular expression patterns throughout the rat brain that 
have not been reported previously. The findings provide a new basis for the 
understanding of CT receptor mediated signalling in major functional circuits 
of the brain. 
2) Peptidergic hypothalamic neurons involved in the regulation of food intake as 
a rule express either CT(a) or CT(b) isoforms. Only occasionally, CT(a) and CT(b) 
are found to be coexpressed in the same neurons. 
3) Orexin neurons selectively express the CT(b), but not the CT(a) isoform. The 
constitutive co-expression of RAMP2, RAMP3 and CT(b) in orexin neurons 
suggests that AMY2(b) and AMY3(b) receptors for amylin and/or CGRP can be 
expressed by orexin neurons. 
4) Orexin cell bodies were found to be targeted by CGRP fibers suggesting that 
CGRP can act as an endogenous brain-derived ligand to directly modulate the 
function of orexin neurons. 
5) Orexin neurons were shown to express the vesicular glutamate transporter 
isoform 2 (VGLUT2), but not GAD67, a marker of GABA-ergic neurons, 
indicating that orexin neurons are glutamatergic and use VGLUT2 to operate 
glutamatergic neurotransmission. This is consistent with the neuroexcitatory 
function of orexin neurons. 
6) Microarray analysis of microdissected orexin neurons from rats subjected to 
fasting revealed 281 genes upregulated (1,32 to 2,61 fold) and 200 genes 
downregulated (1,32 to 2,66 fold), respectively. These regulated genes are 
regarded as novel candidate genes for the regulation of food intake or other 
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functions in orexin neurons. Among the upregulated genes was TRHR1. The 
fasting-induced upregulation of TRHR1 in orexin neurons revealed by 
microarray analysis was successfully validated by quantitative ISH and 
suggests a specific role of TRH in orexin neurons to regulate feeding 
behaviour. 
4.1 Comparative distribution of CT(a) and CT(b) isoforms in rat 
brain 
4.1.1 Regions of the rat brain expressing the CT(a) isoform but not the CT(b) 
isoform 
In regions where no expression of CT(b) was detectable with the specific CT(b) probe, 
the expression and distribution of the CT(a) isoform could be indirectly identified by 
using the CT(a/b) probe. These regions which selectively express the CT(a) isoform as 
indirectly identified with the CT(a/b) probe in nuclei without CT(b) expression included 
the subfornical organ, the lateral substantia nigra, the paratrochlear nucleus, the 
median raphe nucleus, the ventral tegmental nucleus, the parvocellular reticular 
nucleus, the gigantocellular reticular nucleus, the lateral paragigantocellular nucleus, 
and the ventral medullary reticular nucleus. In regions lacking CT(b), this strategy to 
detect the CT(a) isoform with the bi-specific CT(a/b) probe is reliable and can be 
expected to be more sensitive than the usage of an isoform-specific CT(a) 
oligonucleotide probe. 
4.1.2 Direct detection of the CT(a) isoform in the hypothalamus by the newly 
designed CT(a) specific oligonucleotide probe 
Since intense hybridization signals for both CT(b) and CT(a/b) probes were detected in 
the hypothalamus, it is obvious that the CT(b) isoform was expressed in this region. 
Since CT(a) specific riboprobes cannot be generated because of extensive sequence 
homology between CT(a) and CT(b), a CT(a)-specific oligonucleotide probe had to be 
used which allowed to determine the expression of CT(a) directly albeit with 
suboptimal sensitivity. The CT(a) oligonucleotide probe that was newly designed in 
this study, only recognized the CT(a) isoform. In contrast, the oligonucleotide probes 
used by others (Barth et al. 2004) did not differentiate between CT(a) and CT(b) mRNA 
isoforms and, therefore, have to be judged to be unreliable to detect the CT(a) mRNA 
specifically. 
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Using this CT(a) oligonucleotide probe, CT(a) was found to be expressed in 
several hypothalamic nuclei including the dorsomedial hypothalamic nucleus (DMH), 
the ventromedial hypothalamic nucleus (VMH), the arcuate nucleus (ARC) and the 
lateral hypothalamic area (LHA) which are known as centers regulating energy 
homeostasis. These data are the first to unequivocally reveal and localize the CT(a) 
mRNA in these specific nuclei of the brain. 
4.1.3 Distribution of the CT(b) isoform throughout the rat brain 
For the first time, a full distribution map of CT(b) mRNA throughout the rat brain 
employing a highly sensitive ISH method with a specific CT(b) riboprobe was 
established in this thesis. Intense expression of the CT(b) isoform was observed in the 
accumbens nucleus, the lateral septal nucleus, various subdivisions of the amygdala, 
the anterior medial preoptic nucleus, many hypothalamic nuclei, the pericentral dorsal 
tegmental nucleus, the locus coeruleus, the raphe magnus nucleus, the area postrema, 
and the nucleus of the solitary tract.  
Previous studies focused on the expression of CT(b) in circumventricular 
organs of the rat brain (Barth et al. 2004). These authors used oligonucleotide probes 
which are less sensitive as compared to riboprobes. They may have underestimated 
the abundance of CT(b) in the investigated areas. In the mouse brain, the expression of 
CT receptors was investigated previously by in situ hybridization using a CT(a/b) 
riboprobe hybridizing to both the CT(a) and CT(b) mRNAs (Nakamoto et al. 2000). 
These studies generated the view of an overlapping distribution of CT(a) and CT(b). No 
brain region or neuronal population was described to express exclusively CT(b) mRNA. 
4.1.4 Expression of CT(a) and CT(b) isoforms in the area postrema (AP) and 
the nucleus of the solitary tract (NTS) 
Based on in situ hybridization analysis and RT-PCR analysis of microdissected 
specimens of the brainstem, this study has shown for the first time the expression of 
both CT(a) and CT(b) in the AP and NTS and provided strong evidence against the 
previous reports that only CT(a) is expressed in AP and NTS (Hilton et al. 1995; Barth 
et al. 2004).  
The obvious discrepancy to the previous data can be explained by the 
following considerations. In a previous in vitro receptor autoradiography study (Hilton 
et al. 1995), the distribution of CT(a) binding sites in the AP and NTS of the rat brain 
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was revealed by [125I]human calcitonin and that of CT(b) binding sites in these regions 
was shown using [125I]salmon calcitonin in the presence of unlabeled human 
calcitonin and rat amylin under the assumption that human calcitonin could only 
interact with the CT(a) isoform and that amylin cannot bind to calcitonin receptors, 
respectively. However, multiple amylin receptors are known to arise from specific 
associations of calcitonin receptors with the different RAMPs (Christopoulos et al. 
1999; Tilakaratne et al. 2000). This implies that amylin also could bind to calcitonin 
receptors. Therefore, the reported absence of CT(b) binding sites in AP and NTS could 
be due to the binding of unlabeled amylin to this receptor. 
That expression of CT(b) mRNA in the AP and NTS was undectable by ISH 
(Barth et al. 2004) may be due to insufficient sensitivity of oligonucleotide probes 
used. In fact, cRNA probes employed with ISH in the present thesis revealed that both 
CT receptor isoforms CT(a) and CT(b) were expressed in the AP and NTS. This was 
corroborated by RT-PCR analysis of microdissected neurons of the AP and NTS 
which demonstrated presence of both CT receptor transcripts in these regions. 
Therefore, the view of an exclusive expression of CT(a) in the AP and NTS should be 
dismissed. 
4.2 Functional implications of calcitonin receptor isoforms in 
specific brain structures related to the regulation of food 
intake 
The widespread expression of CT receptors in the rat brain as demonstrated in this 
thesis suggests their involvement in a variety of different brain functions. Many of the 
regions with expression of CT(a) or CT(b) or of both isoforms, such as the accumbens 
nucleus, various subdivisions of the amygdala, the brain stem, and many nuclei of the 
hypothalamus, have been reported to be involved in the regulation of food intake 
besides playing a role in the regulation of many other autonomic and limbic functions, 
respectively. 
4.2.1 Expression of calcitonin receptor in the accumbens nucleus 
Using ISH, this study has demonstrated the expression of CT(b) in the accumbens 
nucleus, especially in its shell region. This is consistent with previous RT-PCR results 
which revealed CT(b) transcripts in RNA extracts of the accumbens nucleus (Sexton et 
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al. 1993). In this thesis, the distribution pattern of CT(b) in the accumbens nucleus was 
demonstrated for the first time at the cellular level. Whether CT(a) is also expressed in 
the accumbens nucleus needs to be shown using CT(a)-specific oligonucleotide probes. 
Previous studies have implicated the accumbens nucleus as an important 
region specifically involved in the mediation of feeding behavior. Inhibition of 
neurons in this region by administration of excitatory amino acid antagonists 
(Maldonado-Irizarry et al. 1995) or GABA agonists (Stratford and Kelley 1997) 
elicited intense feeding in satiated rats. Receptor autoradiographic binding studies 
revealed the existence of high affinity binding sites for amylin and CGRP in this 
region (Veale et al. 1994). Infusion of amylin into the rat accumbens nucleus potently 
depressed motor activity and ingestive behavior (Baldo and Kelley 2001). The 
expression of CT receptors in this region suggests that neurons of the accumbens 
nucleus can be directly activated by members of the calcitonin peptide family and that 
CT receptors may be involved in the regulation of addictive behaviour. 
4.2.2 Expression of calcitonin receptor in the amygdala 
In various subdivisions of the amygdala, intense expression of CT(b) mRNA was 
observed for the first time. Whether CT(a) is expressed in this region remains to be 
shown using the CT(a)-specific oligonucleotide probe. 
The amygdala had received early attention in the field of research on food 
intake control because of changes in ingestive behavior following various amygdala 
lesions (Rolls and Rolls 1973; Schoenfeld and Hamilton 1981). Amylin binding sites 
have been detected in the amygdala (Christopoulos et al. 1995). It appears likely that 
circulating amylin modulates feeding behavior via a direct effect on brain areas such 
as the amygdala by acting on CT(b) receptor.  
As the amygdala also serves other functions such as fear, aggression and 
regulation of cardiovascular functions (Baklavadzhyan et al. 2000; Halasz et al. 2002; 
Gale et al. 2004), it is reasonable to postulate that CT(b) mediated signaling may be 
important in this context, too. Under conditions with break down of the blood brain 
barrier as seen in encephalitic conditions (Turkulov et al. 1998), blood borne CT 
receptor ligands may come into playing a role besides intrinsic innervation of the 
amygdala by CGRP fibers (Schwaber et al. 1988). 
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4.2.3 Expression of calcitonin receptors in specific regions of the brain stem 
Both CT(a) and CT(b) were found to be expressed in the area postrema (AP) and the 
nucleus of the solitary tract (NTS). This suggests that neurons of the AP/NTS can be 
modulated by members of the calcitonin peptide family directly. Since the AP and 
probably the NTS lack an effective blood-brain barrier (Luckman and Lawrence 2003), 
the neurons of the AP and NTS expressing the relevant receptors are accessible for 
primary modulation by circulating endogenous ligands such as the pancreas-derived 
amylin. As a partner hormone to insulin, amylin controls nutrient intake by an 
inhibition of food intake (Lutz et al. 1994) and gastric emptying (Reidelberger et al. 
2001) mediated by the AP and NTS (Lutz et al. 1998; Riediger et al. 2004). Thermal 
ablation of the AP and NTS resulted in a significant reduction of the anorectic effects 
of amylin after i.p. injection in rats (Lutz et al. 1998). Chronic amylin infusion in AP 
resulted in the inhibition of food intake in rats. This inhibition was blocked by the 
amylin antagonist AC 187 (Mollet et al. 2004). High-affinity binding sites for [125I]rat 
amylin have been identified in the AP and NTS (Sexton et al. 1994). Moreover, 
RAMP2 and RAMP3 mRNA were observed within AP and NTS regions (Barth et al. 
2004). The association of human CT(a)/CT(b) with RAMP2/RAMP3 seems to be 
essential for amylin binding in vitro (Tilakaratne et al. 2000). However, the co-
localization of these components in the AP and NTS regions in the very same neurons 
and their functional interaction still need to be shown. 
TRH mRNA-expressing neurons are localized in the area postrema and the 
dorsal motor nucleus of the vagus (Heuer et al. 2000). These TRH-positive neurons 
most likely project to the NTS whose intermediate and ventrolateral subdivisions 
contain many TRHR1 mRNA-positive cells (Heuer et al. 2000). TRH binding sites 
have also been reported in the NTS (Manaker and Rizio 1989). However, the 
physiological importance of the expression of TRH and TRH receptor in the dorsal 
vagal complex [area postrema, the dorsal motor nucleus of the vagus (NDV) and the 
nucleus of the solitary tract (NTS)] is not fully understood. Microinjection of TRH 
into the dorsal vagal complex induces dose-dependent increases in gastric acid output 
(Okuma et al. 1987). The results of this thesis showing that CT receptors are not 
expressed in TRH neurons in the AP suggest that the TRH neurons in the AP are 
unlikely to directly respond to the neuropeptides of the calcitonin family. 
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CT receptors are expressed in other brain stem regions such as the locus 
coeruleus (LC). Neurons in the LC have been reported to be involved in many 
physiological and pathophysiological processes, such as arousal, sleep, autonomic 
control, and hypertension (Singewald and Philippu 1998). Peptides of the calcitonin 
superfamily induce multiple biological effects including potent vasodilatation (Poyner 
et al. 2002), sleep (Slisli and de Beaurepaire 1999), and respiratory regulation (Nishi 
et al. 2000). Taken together, CT receptors are likely to be not only involved in the 
regulation of food intake, but also in many other functions. 
4.3 Selective expression of CT receptor isoforms in peptidergic 
neurons of the rat hypothalamus 
This study has demonstrated for the first time that peptidergic hypothalamic neurons 
involved in the regulation of food intake as a rule express either CT(a) or CT(b) 
isoforms. Only occasionally, CT(a) and CT(b) are found to be coexpressed in the same 
neurons. 
4.3.1 Expression of the CT(a) isoform in POMC, CART and CRH neurons of 
the hypothalamus 
The CT(a) isoform was found to be predominantly expressed in POMC, CART and 
CRH neurons of the hypothalamus. POMC, CART and CRH are anorexigenic 
neuropeptides. POMC, expressed in the lateral subpopulation of ARC neurons, 
tonically inhibits food intake via α-melanocyte stimulating hormone (α-MSH), a post-
translational cleavage product of POMC, which functions as melanocortin receptor 
agonist (McMinn et al. 2000). Mutation or polymorphism of the MC-4R gene leads to 
extreme obesity in humans (Hinney et al. 2003). The expression of CT(a) in these 
anorexigenic neurons suggests that the CT(a) isoform may be involved in the 
modulation of the anorexigenic function of these peptidergic neurons. The 
anorexigenic peptides of the calcitonin family may directly act on the POMC/CART 
and CRH neurons via CT(a) to modulate the activation of these neurons related to the 
regulation of food intake. 
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4.3.2 Expression of CT(b) isoform in NPY and orexin neurons of the 
hypothalamus 
The CT(b) isoform was found to be predominantly expressed in NPY and orexin 
neurons in this thesis. NPY is regarded as the most potent orexigenic peptide (Stanley 
et al. 1986; Billington et al. 1991) and the expression of NPY is modulated by leptin 
(Schwartz et al. 1998). Previous studies showed that amylin potently inhibits NPY-
induced feeding (Morris and Nguyen 2001). Orexins are the anabolic signaling 
molecules (Sakurai et al. 1998). The predominant expression of CT(b) in these 
orexigenic neurons suggests that the CT(b) isoform may be involved in the modulation 
of the orexigenic function of these peptidergic neurons. The anorexigenic peptides of 
the calcitonin family may directly act on NPY and orexin neurons via CT(b) to 
modulate the activation of these neurons related to the regulation of food intake. 
4.3.3 Expression of CT(b) isoform in TRH neurons of the paraventricular 
nucleus of the hypothalamus 
This study has demonstrated the expression of CT(b) in a subpopulation of TRH 
neurons in the PVN. TRH neurons are heterogeneous and elicit a variety of 
neuropharmacological effects. They are widely distributed throughout the brain 
(Heuer et al. 2000). In the hypothalamus, TRH neurons are located in the PVN, basal 
part of the anterior and lateral hypothalamus, perifornical area and dorsomedial 
nucleus of the hypothalamus (Kawano et al. 1991). TRH has been implicated in the 
control of food intake (Suzuki et al. 1982; Steward et al. 2003). Central administration 
of TRH reduces food intake (Steward et al. 2003). Fasting decreases the expression of 
proTRH mRNA in the PVN (Blake et al. 1991). The expression of CT(b) in TRH 
neurons of PVN suggests that the CT(b) isoform may be involved in the modulation of 
the anorexigenic function of the TRH neurons in the PVN. 
However, TRH neurons in different regions of the hypothalamus may have 
different functions. For example, TRH has been reported to be involved in the 
pathophysiology of narcolepsy. Two stabilized TRH analogs (CG3703 and TA0910) 
significantly increase wakefulness and decrease sleep in narcoleptic canines (Nishino 
et al. 1997). The peptides of the calcitonin family have also been found to affect the 
sleep cycles (Slisli and de Beaurepaire 1999). It is unclear whether the TRH neurons 
in other than the PVN area express the CT receptors and modulate mutiple functions 
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of the peptides of the calcitonin family. These questions remain to be further 
investigated. 
4.3.4 Differences of ligand-binding kinetics and receptor specificity of CT(a) 
and CT(b) isoforms 
The CT(a) and CT(b) isoforms have different ligand-binding kinetics and receptor 
specificity. In previous competition binding studies, while both receptor isoforms bind 
to salmon calcitonin with high affinity, only the CT(a) receptor interacts with human 
calcitonin (Hilton et al. 1995). Calcitonin receptors in man and rodents have the 
highest affinity and efficacy for calcitonin peptides (Poyner et al. 2002). In association 
with RAMPs, calcitonin receptors can function as amylin or as CGRP receptors 
(Christopoulos et al. 1999; Muff et al. 1999). In vitro all three RAMPs will interact 
with CT(a) and CT(b) receptors to generate amylin receptors, while the CT(b)/RAMP2 
displays greater affinity to amylin than that of CT(a)/RAMP2 depending on the host 
cell environment (Tilakaratne et al. 2000). Amylin receptors with varying affinity for 
CGRP have been observed in competition binding studies in rat brain (van Rossum et 
al. 1994). These may arise from interaction of CT receptors with different RAMPs. In 
order to clarify the ligands of the CT receptor isoforms in the peptidergic neurons of 
the hypothalamus, the coexpression patterns of the RAMPs with CT receptor isoforms 
in orexin neurons have been investigated. 
4.4 Functional implications of CT(b) isoform expression in 
orexin neurons 
4.4.1 Expression of AMY2(b) and AMY3(b) receptors in orexin neurons 
For the first time, this study has shown that the CT(b) isoform, but not the CT(a) 
isoform, and RAMP2 and RAMP3 are expressed in virtually all orexin neurons in the 
LHA. The coexpression of CT(b) with RAMP2 and RAMP3 in orexin neurons as 
demonstrated in this thesis suggests that the amylin receptor subtypes AMY2(b) and 
AMY3(b) are expressed in orexin neurons. 
Orexin neuropeptides are anabolic signaling molecules. Intracerebroventricular 
(icv) administration of orexin A consistently stimulates food intake, but that of orexin 
B has such effects only on occasions. Both orexin A and orexin B peptides stimulate 
food intake significantly less than NPY but to a similar extent as MCH (Edwards et al. 
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1999). The expression of AMY2(b) and AMY3(b) receptors in the orexin neurons 
suggests that peptides of the anorexigenic calcitonin family may directly act on orexin 
neurons to modulate the function of orexin neurons related to food intake. 
4.4.2 Amylin is a possible ligand for AMY2(b) or AMY3(b) receptors in orexin 
neurons 
Previous studies reported that the expression of orexin, but not that of MCH, is 
downregulated by intraperitoneal injection of amylin (Barth et al. 2003). Neurons in 
the LHA were inhibited in response to food intake and intraperitoneal administration 
of amylin (Riediger et al. 2004). The present study has demonstrated that important 
molecular components necessary for the amylin binding are expressed in orexin 
neurons, which makes them one of the primary CNS targets for circulating amylin. 
Previous studies reported that amylin acts as a physiological peripheral satiety agent to 
regulate short-term food intake (Morley et al. 1995; Arnelo et al. 1996; Reidelberger 
et al. 2004). Furthermore, amylin delivers adiposity signals to the brain to regulate 
long-term energy homeostasis (Rushing 2003). 
However, amylin is not expressed in brain resident neurons and it is still 
unclear how amylin from the periphery may gain access to orexin neurons. One 
possibility is that amylin enters the brain by crossing the blood brain barrier by yet 
unknown transport mechanisms. Another possibility is that amylin enters the brain 
through the ARC of the hypothalamus or by the AP of the brain stem where the blood 
brain barrier is open. These questions need to be further investigated. 
4.4.3 Is CGRP the brain-derived ligand for AMY2(b) or AMY3(b) receptors in 
orexin neurons? 
Since CGRP but not amylin is expressed in brain, CGRP has to be considered as a 
likely brain-derived ligand for amylin receptors. In fact, double 
immunohistochemistry performed in this thesis has revealed that CGRP positive 
terminals are present in the lateral hypothalamus contacting the cell bodies and 
processes of the orexin neurons strongly suggesting the possibility that CGRP acts as 
an endogenous ligand on orexin neurons. Whether CGRP can bind to AMY2(b) or 
AMY3(b) or to both receptors in vivo to directly activate orexin neurons remains to be 
further investigated. 
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CGRP shares considerable structural and functional homology with amylin. 
CGRP reduces food intake after central and peripheral administration (Krahn et al. 
1984; Morley et al. 1996). Peripheral CGRP is less effective than centrally 
administered CGRP (Krahn et al. 1984). Lesions of the AP and NTS have been shown 
to reduce the anorectic effects of both amylin and CGRP peptides when injected 
intraperitoneally (ip) (Lutz et al. 1998). However, a lesion in the AP and NTS region 
did not influence the anorectic effects of amylin and CGRP after administration into 
the lateral ventricle (Lutz et al. 1998). Therefore, calcitonin receptors/RAMPs 
complex in the forebrain may mediate the anorectic effects of both peptides when 
administered centrally. 
This study has also shown that CGRP fibers form close spatial relationships 
with orexin fibers in the posterior paraventricular thalamic nucleus (PVP). With 
afferents from brainstem and hypothalamic cell groups, including the lateral 
hypothalamic area and efferents to limbic centers, the PVP is in a position to integrate 
visceral and circadian information, and to modulate limbic functions. That the PVP is 
involved in food intake and weight gain in rats was reported (Bhatnagar and Dallman 
1999). Previous studies have shown that dense populations of orexin-containing fibers 
are present in the PVP, but their role is largely unknown (Date et al. 1999). The close 
spatial relationship of CGRP and orexin fibers in this area as shown in this thesis for 
the first time may suggest that these two neuropeptides cooperate in the regulation of 
functions of the PVP. 
4.4.4 Relationship between orexin neurons and other hypothalamic 
peptidergic neurons 
MCH is a critical regulator of feeding which acts downstream of leptin and the 
melanocortin system (Shimada et al. 1998). Orexin and MCH perikarya have been 
found in close proximity to each other, and synaptic contacts have been observed 
between them (Bayer et al. 2002). OX1R is expressed in MCH neurons (Backberg et 
al. 2002). It is likely that these two neuronal populations communicate within the 
LHA in an interrelated fashion. The selective expression of CT(b) in orexin neurons, 
but not in MCH neurons, suggests that peptides of the calcitonin family probably can 
not directly activate MCH neurons. Whether peptides of the calcitonin family could 
modulate the function of the MCH neurons via orexin neurons remain to be shown. 
CART is colocalized with MCH in this area (Broberger 1999). The lack of CT 
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receptors in both CART and MCH neurons as demonstrated in this thesis are in 
concordance with these results.  
Orexin neurons have reciprocal connections to the neurons of the arcuate and 
paraventricular nuclei. Orexin-containing fibers are present in the paraventricular 
nucleus (PVN) and the arcuate nucleus (Date et al. 1999). Orexins can directly interact 
with NPY and POMC neurons to regulate Ca 2+ signaling (Muroya et al. 2004). 
Orexin A was found to enhance food intake when injected into the paraventricular 
nucleus (PVN) (Dube et al. 1999). Whether peptides of the calcitonin family could 
modulate the function of the NPY and POMC neurons in ARC and the CRH and TRH 
neurons in PVN via orexin neurons remains to be shown. 
4.5 Identification of a specific glutamatergic phenotype of 
orexin neurons 
Electrophysiological studies suggested that the secretion of orexin is autostimulated 
via enhancing the release of glutamate from neurons in synaptic contact with orexin 
neurons (Li et al. 2002). However, the possibility that orexin neurons themselves 
release glutamate could not be excluded. In fact, glutamate immunoreactivity has been 
reported in orexin neurons (Li et al. 2002). However the presence of glutamate in 
orexin neurons does not necessarily prove that immunodetected glutamate is related to 
vesicular release of glutamate or to glutamate metabolism. 
Like other neurotransmitters glutamate is packaged into synaptic vesicles 
before its release from presynaptic terminals by a vesicular transport system (Storm-
Mathisen et al. 1983) Three different vesicular glutamate transporter proteins 
(VGLUT1-3) which transport glutamate into the synaptic vesicles represent unique 
markers for glutamatergic neurons (Reimer and Edwards 2004). The predominant 
vesicular glutamate transporter in the hypothalamus is VGLUT2 (Bai et al. 2001; Gras 
et al. 2002; Schafer et al. 2002; Takamori et al. 2002; Varoqui et al. 2002). 
In this thesis it could be demonstrated that VGLUT2 mRNA, but not GABA 
synthetic enzyme glutamate decarboxylase (GAD) mRNA is expressed in all orexin 
neurons strongly indicating that orexin neurons have a specific VGLUT2 coded 
glutamatergic phenotype. These results suggest that orexin neurons themselves have 
the capacity for vesicular accumulation and release of glutamate implying the 
possibility that the released glutamate may autostimulate orexin neurons. 
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The finding that orexin neurons are glutamatergic is consistent with their 
known neuroexcitatory properties. In addition to their role in the control of energy 
homeostasis (Sakurai et al. 1998), orexin neurons have been implicated in other 
physiological functions, such as arousal maintenance (Hagan et al. 1999), analgesia 
(Bingham et al. 2001), endocrine function (Al-Barazanji et al. 2001), autonomic 
regulation (Davis et al. 2003) and the regulation of synaptic transmission and 
plasticity (Selbach et al. 2004). The excitatory neurotransmitter glutamate is known to 
be involved in these functions. Intravenous orexin administration causes a marked and 
sustained increase in glutamate release within the amygdala, a limbic region related to 
the feeding (Schoenfeld and Hamilton 1981) and sleeping (John et al. 2003). The 
arousal effects of orexin-A correlate with glutamate release from the locus coeruleus 
(Kodama and Kimura 2002). Orexin regulates motor control processes and this 
regulation is mediated by glutamate release in the trigeminal motor nucleus (Peever et 
al. 2003). The effects of orexin A on magnocellular neurones of PVN are mediated by 
the activation of glutamate interneurons (Follwell and Ferguson 2002). The effects of 
orexin B in modulating autonomic sensory signaling in the NTS are mediated by the 
release of glutamate in the NTS (Smith et al. 2002). The glutamatergic transmission is 
also reported to associate with the modulation of synaptic plasticity of orexins in the 
hippocampus (Selbach et al. 2004). 
4.6 Possible functional implications of transcriptomic 
changes in orexin neurons after fasting 
The pilot microarray analysis of differential gene expression in microdissected orexin 
neurons performed in this thesis revealed about 281 upregulated and 200 
downregulated genes in orexin neurons after fasting. Among these genes, many 
enzymes, channels, receptors, neuropeptides and structural molecules were identified 
to be regulated after fasting. This study is the first to specifically assess fasting-
induced gene regulation in orexin neurons. 
4.6.1 Validation of the expression and upregulation of TRHR1 in orexin 
neurons 
In principle, all regulated genes after fasting can be regarded as novel candidate genes 
for the regulation of food intake by orexin neurons. Among these genes, TRHR1 was 
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found to be expressed in orexin neurons and upregulated 1,5 fold after fasting. Using 
semi-quantitative in situ hybridization, the regulation of TRHR1 seen in microarray 
analysis has been validated in this study to amount to a 1,24-fold increase. These 
findings clearly indicate that the microarray approach in this thesis to test differential 
gene expression in microdissected neurons of rats subjected to fasting and of untreated 
rats was extremely powerful and accurate to reveal even very subtle changes of 
TRHR1 that matched changes determined by quantitative analysis with ISH. Although 
these changes are subtle they can be regarded to be of physiological relevance because 
minor changes in neuropeptide expression can have important physiological 
consequences (e.g. substance P, CGRP changes in primary sensory pain pathways, 
(Nohr et al. 1999)). 
The effects of TRH are mediated by two TRH receptors, which display 
complementary distribution patterns in the brain (Heuer et al. 2000). It has been 
reported that in a subpopulation of magnocellular neurons of the lateral hypothalamic 
area only mRNA for TRHR1, but not for TRHR2 could be detected. Low levels of 
TRHR2 mRNA were observed in smaller neurons in the lateral hypothalamic area 
(Heuer et al. 2000). However, the phenotypes of these neurons which express TRHR1 
and TRHR2 in the LHA remained unknown. The present study has demonstrated that 
virtually all orexin neurons in the LHA express TRHR1 but not TRHR2 mRNA. 
These data are the first to identify the phenotype of neurons which express TRH 
receptor in the lateral hypothalamic area. 
Microinjection of TRH into the medial and lateral hypothalamus produces 
severe anorexia (Suzuki et al. 1982). The expression of TRHR1 in orexin neurons and 
upregulation by fasting suggests that TRH may directly act on orexin neurons via 
TRHR1 to modulate the activation of orexin neurons related to the regulation of food 
intake. Under fasting conditions, the increased expression of the TRHR1 in orexin 
neurons may induce an increased binding of TRH to TRHR1 to modulate the 
orexigenic tone. 
In addition to its role in the control of energy homeostasis, TRH has been 
implicated in other physiological functions, including thermoregulation (Boschi and 
Rips 1981), respiratory and cardiovascular function (Koivusalo et al. 1979), locomotor 
activity (Kalivas et al. 1987), arousal (Breese et al. 1975; Horita 1998), and sleepiness 
(Nishino et al. 1997). Orexin neurons are known to be involved in these functions 
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(Date et al. 1999; Hagan et al. 1999; Davis et al. 2003). Therefore, the TRH may 
modulate the multiple functions of orexin neurons via TRHR1. 
4.6.2 Possible functional implications of some candidate genes regulated 
after fasting 
The present thesis has identified a number of novel candidate genes that are worth to 
be tested further. For example, among these genes, insulin-like growth factor I (IGF-I) 
receptor and gamma-aminobutyric acid (GABA) B receptor 1 were found to be 
expressed in orexin neurons and upregulated 1,55 fold and 1,47 fold after fasting, 
respectively. In fact, both genes have been found to play a role in the regulation of 
food intake. 
The IGF-I is a potent anabolic hormone. Its concentrations in serum are 
increased in response to food intake and decreased in states of chronic undernutrition 
or when food intake is restricted (Morovat et al. 1994). Previous in vitro 
autoradiography studies reported that the IGF-I receptor was expressed in the median 
eminence of the rat brain and modulated by food restriction (Bohannon et al. 1988). 
The binding of 125I-labeled [Thr59]IGF-I in the median eminence was significantly 
increased in the food restricted rats due to an increase in the concentration of iodo-
[Thr59]IGF-I-binding sites in the median eminence (Bohannon et al. 1988). The 
present thesis is the first study to identify the expression and regulation of IGF-I 
receptor in orexin neurons. This indicates the new concept that IGF-I may directly 
modulate the activity of orexin neurons. Under fasting conditions, the increased 
expression of the IGF-I receptor in orexin neurons may cause increased binding of the 
IGF-I to this receptor to modulate the orexigenic tone. 
The microarray analysis for the first time revealed that GABA(B)R1 mRNA is 
expressed in orexin neurons. This is consistent with a previous immunoreactive study 
that described the GABA(B)R1 immunoreactivity in orexin neurons (Backberg et al. 
2003). GABA has been reported to stimulate feeding via both ionotropic GABA(A) 
and metabotropic GABA(B) receptors. The functional form of the GABA(B) receptor 
is a heterodimer consisting of GABA(B) receptor-1 (GABA(B)R1) and GABA(B) 
receptor-2 (GABA(B)R2) proteins. Within the heterodimer, the GABA-binding site is 
localized to GABA(B)R1. A previous report that intraperitoneal and 
intracerebroventricular administration of the GABA(B) receptor antagonist CGP 
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35348 reduced food consumption in rats (Patel and Ebenezer 2004) suggests the 
involvement of central GABA(B) receptor in the regulation of feeding behaviour. 
Orexin neurons regulate the feeding behaviour also through GABAergic 
circuits (Viggiano et al. 2004). Intracerebroventricular injection of orexin A increased 
extracellular GABA in the medial hypothalamus (Viggiano et al. 2004). The orexin 
neurons in the hypothalamus are densely surrounded by GABAergic nerve endings, 
which are likely to originate from several different sources (Backberg et al. 2003). 
Since the GABA(B)R1 is expressed in orexin neurons as indicated in this study, 
GABA may influence the release of orexins via GABA(B)R1-mediated mechanisms. 
4.6.3 Possible functional implications of some candidate genes unregulated 
after fasting 
The observation that prepro-orexin was found to be expressed in the microdissected 
orexin neurons indicates that the LCM-microarray strategy employed was accurate. 
However the orexin gene itself was not subject to fasting-induced regulation in orexin 
neurons. 
Previous studies reported that prepro-orexin gene expression either increased 
(Sakurai et al. 1998) or remained unaffected after fasting (Swart et al. 2001; Tritos et 
al. 2001; Bertile et al. 2003). Northern blot analysis of total RNA from rat 
diencephalon revealed that the expression of prepro-orexin mRNA was upregulated 
2.4 fold in male Wistar rats fasted for 48h (Sakurai et al. 1998). In contrast, in situ 
hybridization and immunohistochemistry showed that prepro-orexin mRNA levels and 
orexin-A immunoreactivity were unaffected in male Sprague Dawley rats fasted for 
48h (Swart et al. 2001). Moreover, it has been reported that 4 days or 5-7 days food 
deprivation did not induce significant changes in prepro-orexin mRNA levels in male 
Sprague Dawley rats analyzed by in situ hybridization (Bertile et al. 2003). The 
expression of prepro-orexin mRNA in male C57BL/6J mice fasted for 60h was also 
unaffected as measured by in situ hybridization histochemistry (Tritos et al. 2001).  
The reason for discrepancies between previous studies and data in this thesis 
are most likely due to species (mouse vs. rat) or technical differences (Northern blot 
analysis vs. in situ hybridization and microarray analysis). Unchanged levels of 
prepro-orexin mRNA after fasting would be consistent with the need to spare energy 
during fasting. Indeed, in transgenic mice, orexin overexpression results in decreased 
body weight despite increased food intake due to inappropriately increased metabolic 
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rate whereas orexin-deficient mice show slightly reduced body weight despite 
markedly reduced food intake due to decreased metabolic rate (Inui 2000). 
Other genes demonstrated by ISH in this study, such as the calcitonin receptor, 
receptor-activity-modifying proteins and the vesicular glutamate transporter were also 
revealed to be expressed in orexin neurons by microarray analysis. Although the 
expression of these genes was not affected after fasting according to microarray 
analysis, the involvement of these genes in the regulation of feeding behaviour is 
conceivable as discussed above. The cellular and molecular mechanisms of these 
genes in relation to food intake, and other functions in association with orexin neurons 
need to be further investigated. 
4.6.4 Perspectives of the data obtained by microarray analysis of 
microdissected orexin neurons 
It was beyond the scope of this thesis to validate the regulation of all the other genes 
(including those appearing as ESTs) found by microarray analysis. It is obvious that 
further extensive experiments are required assessing gain and loss of function with the 
help of siRNA technologies, new knockout animals and new transgenic models 
overexpressing genes in question as well cell culture approaches with single cell PCR 
analysis to determine the functional and mechanistic roles of the various novel 
candidate genes in relation to food intake and other functions beyond food intake 
regulation. With such strategies it should be possible to unravel distinct specific 
functions of these candidate genes with respect to enhancing or reducing appetite, 
stimulating or inhibiting energy expenditure, taking part in the short- or long- term 
effects of food intake regulation etc. Moreover, it may be possible to determine the 
involvement of these genes in many other functions than regulation of energy 
homeostasis, e.g. regulation of arousal, sleep, autonomic control, and hypertension. It 
will be an enormous task to clarify the probably diverse functions of the different 
candidate genes in orexin neurons requiring gene by gene analysis which obviously 
was beyond the scope of this thesis. Nevertheless, the strategy to perform cell-specific 
functional transcriptomic analysis seems to be more promising than transcriptomic 
analysis of crude hypothalamic extracts that do not pay tribute to the vast anatomical 
and functional heterogeneity of hypothalamic nuclei and neurons. Implicitly, 
microarray analysis of the phenotype-identified cell groups in the hypothalamus and 
brain stem related to the regulation of food intake are likely to prove valuable to 
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discover, validate and functionally characterize genes with so far unknown relevance 
in the regulation of food intake and energy expenditure. In any case, such 
investigations will lead to a better understanding of the molecular, cellular and 
functional specificity of hypothalamic and brainstem circuits. 
94 
Summary 
 
5 Summary 
The hypothalamus and brainstem are regarded as key centers of the brain that regulate 
energy homeostasis including food intake. Activation of these central 
neuropeptidergic pathways with orexigenic or anorexigenic properties by hormonal, 
nerval and nutrient stimuli exerts powerful effects on food intake. Among these 
neuropeptides are the members of the calcitonin/CGRP family, e.g. calcitonin (CT), 
amylin and calcitonin gene-related peptide (CGRP), which are ligands for receptor 
complexes consisting of CT receptor isoforms and receptor-activity-modifying 
proteins (RAMPs). There is evidence that the calcitonin/CGRP family and their 
receptors play a role in the regulation of food intake and long-term energy 
homeostasis. As no systematic analysis of the distribution of CT receptor isoforms 
throughout the brain is available, it is not fully understood how and where the peptides 
of the calcitonin family and their receptors participate in these feeding circuits.  
Therefore, it was the aim of this thesis to characterize the distribution of CT 
receptor isoforms in the rat brain and, in particular, to answer the question whether 
peptides of the calcitonin family can directly act on peptidergic neurons in the 
hypothalamus, the area postrema (AP) and the nucleus of the solitary tract (NTS). For 
this purpose, RT-PCR in combination with laser capture microdissection (LCM), in 
situ hybridization (ISH), and immunocytochemistry were employed to determine the 
cell-specific expression pattern of the CT receptor isoforms CT(a) and CT(b) throughout 
the brain and especially in nuclei of the hypothalamus and brain stem relevant for 
feeding behavior. With particular emphasis, the orexin neurons in the lateral 
hypothalamic area were investigated. In order to identify novel candidate genes 
involved in the regulation of food intake in the hypothalamus, orexin neurons from 
fasting and non-fasting rats were laser microdissected and the differential gene 
expression was determined by microarray analysis. 
The following essential new findings and conclusions have been obtained: 
1. Both CT(a) and CT(b) were found to be expressed in the rat brain. They exhibit 
distinct differences in their expression patterns. While CT(a) was found to be 
widely expressed throughout the brain consistent with a wide variety of functions 
exerted by members of the calcitonin family, CT(b) showed a more restricted 
expression pattern suggesting more limited functions for CT(b) mediated 
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neurotransmission. CT(b) was predominately expressed in the hypothalamus and 
brain stem.  
2. Peptidergic hypothalamic neurons, as a rule, expressed either CT(a) or CT(b) 
isoforms. NPY neurons, orexin neurons and a subpopulation of TRH neurons 
predominately expressed the CT(b) isoform, while the CT(a) isoform was 
selectively expressed in a subpopulation of POMC/CART neurons and CRH 
neurons. CT receptors were absent from TRH neurons in the area postrema (AP). 
3. Co-expression of CT(b) with RAMP2 and RAMP3 in orexin neurons suggests that 
functional amylin receptor subtypes AMY2(b) and AMY3(b) are expressed in orexin 
neurons. These data indicate a role of amylin and/or CGRP in the modulation of 
orexin neurons. 
4. Double immunohistochemistry demonstrated that in the lateral hypothalamus 
CGRP positive terminals contact orexin neurons indicating that CGRP may act as 
an endogenous ligand on orexin neurons. 
5. The expression of vesicular glutamate transporter 2 in virtually all of the orexin 
neurons in the LHA clearly indicates that orexin neurons have a glutamatergic but 
not a GABAergic phenotype. 
6. LCM Microarray analysis of microdissected orexin neurons from animals 
subjected to fasting has led to the identification of 481 novel candidate genes that 
regulate feeding behavior at the level of orexin neurons. Among the regulated 
genes were thyrotropin releasing hormone receptor 1 (TRHR1), insulin-like 
growth factor 1 receptor, and gamma-aminobutyric acid (GABA) B receptor 1. By 
in situ hybridization, the regulation of TRHR1 was validated. 
7. The expression of TRHR1 in orexin neurons, but not TRHR2, and the 
upregulation of TRHR1 mRNA after fasting suggest that TRH may influence 
energy homeostasis by directly acting on orexin neurons via TRHR1. 
Taken together, CT receptor isoforms are likely to play an important and isoform-
specific role throughout the brain and especially in feeding circuits of the 
hypothalamus and brain stem. As these circuits also serve other functions than 
regulation of energy homeostasis, e.g regulation of sleep, autonomic functions and 
arousal, CT receptors are probably involved in an isoform-sepcific manner to 
modulate such functions, too. Likewise, the genes found to be regulated in orexin 
neurons after fasting can be postulated to play a role beyond functions of orexin 
neurons related to food intake. 
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6 Zusammenfassung 
Hypothalamus und Hirnstamm gelten als Schlüsselzentren des Gehirns für  die 
Regulation der Energie-Homöostase einschließlich der Nahrungsaufnahme. Eine 
Beeinflussung seiner neuropeptidergen Schaltkreise, die sowohl orexigene als 
anorexigene Komponeneten haben, durch hormonelle und nervale Faktoren sowie 
durch Nährstoffe übt einen starken Einfluss auf die Nahrungsaufnahme aus. Vieles 
deutet darauf hin, dass Neuropeptide der Calcitonin/CGRP-Familie zur zentralen 
Regulation der Nahrungsaufnahme und des langfristigen Energiegleichgewichts 
beitragen. Mitglieder der Calcitonin/CGRP-Familie sind Calcitonin (CT), Amylin und 
"Calcitonin gene-realted peptide"(CGRP). Sie fungieren als Liganden für Rezeptor-
Komplexe, die aus verschiedenen Isoformen des CT-Rezeptors und der "receptor-
activity-modifying proteins" (RAMPs) bestehen. Wie und wo diese Neuropeptide und 
ihre Rezeptoren Schaltkreise des Essverhaltens modulieren, blieb angesichts des 
Fehlens systematischer Expressionanalysen bisher ungeklärt. 
Deshalb war es das Ziel dieser Dissertation,  die Verteilung der CT-Rezeptor-
Isoformen im Rattenhirn zu charakterisieren, und insbesondere die Frage zu 
beantworten, ob Peptide der CT-Familie auf peptiderge Neurone des Hypothalamus, 
der Area postrema (AP) und des Nucleus tractus solitarii eine direkte Wirkung 
entfalten können. Zu diesem Zweck wurden Methoden der RT-PCR in Kombination 
mit Laser-Capture-Microdissektion (LCM), In situ-Hybridisierung (ISH) und 
Immunhistochemie (ICC) eingesetzt, um die zellspezifischen Expressionsmuster der 
CT-Rezeptor-Isoformen im gesamten Rattenhirn, insbesondere in den Kerngebieten 
des Hypothalamus und des Hirnstamms, die für das Essverhalten wichtig sind, zu 
bestimmen. Mit besonderer Gewichtung wurden die Orexin-Neurone in der lateralen 
hypothalamischen Region (LHA) untersucht. Um neue Kandidatengene zu 
identifizieren, die an der Regulation der Nahrungsaufnahme im Hypothalamus 
beteiligt sind, wurden Orexin-Neurone von Ratten mit und ohne Nahrungskarenz 
lasermicrodissektiert, um deren  differenzielle Genexpression mittels Microarray-
Analyse zu bestimmen. 
Die folgenden grundlegenden Erkenntnisse wurden gewonnen und folgende 
Schlussfolgerungen gezogen: 
1) Beide CT Rezeptor-Isoformen, CT(a) und CT(b), sind im Gehirn exprimiert mit 
klaren Unterschieden in ihrem Expressionsmuster. Während CT(a) im Rattenhirn weit 
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verbreitet ist, was im Einklang mit der Vielzahl an Funktionen der CT-Peptidfamilie 
steht, zeigt CT(b) ein eingeschränkteres Expressionsmuster mit bevorzugter Expression 
im Hypothalamus und Hirnstamm, was auf begrenzte Funktionen der CT(b)-
vermittelten Neurotransmission hindeutet. 2) Peptiderge hypothalamische Neurone 
exprimieren in der Regel entweder die CT(a)-oder die CT(b)-Isoform. NPY-Neurone, 
Orexin-Neurone und eine Subpopulation der TRH-Neurone exprimieren überwiegend 
die CT(b)-Isoform, während die CT(a)-Isoform in einer Subpopulation von 
POMC/CART- und CRH-Neuronen exprimiert wird. Hingegen finden sich keine CT-
Rezeptoren auf den TRH-Neuronen in der AP. 3) Die Ko-expression von CT(b) mit 
RAMP2 und RAMP3 in Orexin-Neuronen weist auf die Möglichkeit der funktionellen 
Expression der Amylin-Rezeptorsubtypen AMY2(b) und AMY3(b) in diesem Zelltyp 
hin. 4) Mit ICC-Doppelmarkierung konnte gezeigt werden, dass in der LHA CGRP-
positive Endigungen Orexin-Neurone kontaktieren, was auf CGRP als möglichen 
endogenen Liganden hindeutet. 5) Die Expression des vesikulären Glutamat-
transporters 2 in nahezu allen Orexin-Neuronen zeigt eindeutig, dass Orexin-Neurone 
einen glutamatergen Phänotyp haben. 6) Microarray-Analyse microdissektierter 
Orexin-Neurone von Ratten nach 48h Fasten führte zur Identifizierung 481 neuer 
Kandidatengene, die das Essverhalten auf zellulärer Ebene in Orexin-Neuronen 
möglicherweise regulieren. Darunter befanden sich der Thyreotropin-Rezeptor Typ 1 
(TRHR1), "Insulin-like growth factor 1" Rezeptor, GABA (B)-Rezeptor 1. Mittels 
semi-quantitativer ISH wurde die Regulation von TRHR1 validiert. 7) Die Expression 
von TRHR1, jedoch nicht TRHR2, und die gering erhöhten TRHR1 mRNA-Spiegel in 
Orexin-Neuronen nach 48stündigem Fasten weisen auf eine Rolle von TRH bei der 
Regulation des Energiegleichgewichts durch direkte TRHR1-vermittelte Wirkung auf 
Orexin-Neurone hin. 
Insgesamt bedeuten die hier erzielten Ergebnisse, dass CT-Rezeptoren eine 
wichtige und wahrscheinlich isoform-spezifische Rolle im Gehirn spielen, ins-
besondere in den Schaltkreisen der Ernährungsregulation im Hypothalamus und im 
Hirnstamm. Da diese Schaltkreise auch anderen Funktionen dienen, wie z.B. der 
Regulation von Wachheit und Schlaf und weiterer vegetativer Funktionen, ist es wahr-
scheinlich, dass CT-Rezeptoren isoform-spezifisch auch diese Funktionen modulieren 
können. Ebenso kann man davon ausgehen, dass die Gene, deren Expression in Orexin-
Neuronen nach Fasten verändert war, auch eine Rolle bei anderen Funktionen der 
Orexin-Neurone über die Regulation der Nahrungsaufnahme hinaus spielen. 
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8 Abbreviations 
All units of measurement are abbreviated according to the International System of 
units (SI). 
AC adenylyl cyclase 
Acb accumbens ncl. 
AgRP Agouti-gene-related protein 
AHA anterior hypothalamic area 
AHC anterior hypothalamic area, central 
AMPO anterior medial preoptic ncl. 
AP area postrema 
Arc arcuate hypothalamic ncl. 
BCIP 5-bromo-4-chloro-3-indolyl-phosphate-4-toluidine salt 
BSA acetylated bovine serum albumin 
BST bed nucleus of the stria terminalis 
BSTIA bed nucleus of the stria terminalis, intraamygdaloid div 
CART cocaine- and amphetamine-regulated transcript 
CCK cholecystokinin 
CeM central amygdaloid ncl., med div 
CGRP calcitonin-gene-related peptide 
CNS central nervous system 
CRH corticotropin-releasing hormone 
CRLR calcitonin receptor-like receptor 
CT calcitonin 
DA dorsal hypothalamic area 
DAB 3,3 diaminobenzidine tetrahydrochloride 
DEPC diethyl pyrocarbonate 
DMH dorsomedial hypothalamic ncl. 
DMSO dimethyl sulfoxide 
DMTg dorsomedial tegmental area 
dNTP deoxynucleoside triphosphate 
DR dorsal raphe ncl. 
DTgP dorsal tegmental ncl., pericentral 
DTT dithiothreitol 
EDTA ethylene diaminetetraacetic acid 
fr fasciculus retroflexus 
GABA γ-aminobutyric acid 
GAD glutamate decarboxylase 
Gi gigantocellular reticular ncl. 
GLP1 glucagon-like peptide 1 
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GPCR G-protein-coupled receptor 
HEPES (2-Hydroxyethyl)-1-piperazineethanesulphonic acid 
IPTG Isopropylthio-β-D-galactoside 
LA lateroanterior hypothalamic ncl. 
LC locus coeruleus 
LDTg laterodorsal tegmental ncl. 
LH lateral hypothalamic area 
LHb lateral habenular ncl. 
LPB lateral parabrachial ncl. 
LPGi lateral paragigantocellular ncl. 
LRt lateral reticular ncl. 
LSV lateral septal ncl. 
MCH melanin-concentrating hormone 
MdV medullary reticular ncl., ventral 
Me medial amygdaloid ncl. 
MeAD medial amygdaloid nucleus, anterodorsal 
MeAV medial amygdaloid nucleus, anteroventral 
MePD medial amygdaloid nucleus, posterodorsal 
MePV medial amygdaloid nucleus, posteroventral 
MnPO median preoptic ncl. 
MnR median raphe ncl. 
MPA medial preoptic area 
MPO medial preoptic ncl. 
MSH melanocyte-stimulating hormone 
NBT 4-nitroblue - tetrazol - chloride 
NPY neuropeptide Y 
NTS nucleus of the solitary tract 
Pa4 paratrochlear ncl. 
PaAP paraventricular hypothalamic ncl., ant parvo 
PACAP pituitary adenylate cyclase-activating peptide 
PCR Polymerase chain reaction 
PCRt parvocellular reticular ncl. 
Pe periventricular hypothalamic ncl. 
PeF perifornical ncl. 
PKC protein kinase C 
POMC pro-opiomelanocortin 
PPTg pedunculopontine tegmental ncl. 
PTH parathyroid hormone 
PVN paraventricular hypothalamic ncl. 
RAMP receptor-activity-modifying-protein 
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RMg raphe magnus ncl. 
ROb raphe obscurus ncl. 
RPa raphe pallidus ncl. 
RtTg reticulotegmental nucleus pons 
SCh suprachiasmatic ncl. 
SDS sodium dodecyl sulfate 
SFO subfornical organ 
SHy septohypothalamic ncl. 
SPTg subpeduncular tegmental ncl. 
SSC standard sodium citrate buffer 
StHy striohypothalamic ncl. 
SubCD subcoeruleus nucleus, dorsal 
TEA triethanolamine 
TEMED tetramethyl ethylene diamine 
TESAP 3-(Triethoxysilyl) propylamine 
TRH thyrotropin-releasing hormone 
Tris Tris (hydroxymethyl) aminomethane 
VGLUT vesicular glutamate transporter protein 
VMH ventromedial hypothalamic ncl. 
VTg ventral tegmental ncl. 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
3V third ventricle 
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